{"id":5,"date":"2018-01-09T22:22:53","date_gmt":"2018-01-09T22:22:53","guid":{"rendered":"https:\/\/my.dev.vanderbilt.edu\/niswenc\/cv\/"},"modified":"2018-01-17T17:16:51","modified_gmt":"2018-01-17T22:16:51","slug":"cv","status":"publish","type":"page","link":"https:\/\/my.dev.vanderbilt.edu\/niswenc\/cv\/","title":{"rendered":"Curriculum Vitae"},"content":{"rendered":"

CURRICULUM VITAE<\/u><\/strong><\/p>\n

Colleen M. Niswender, Ph.D.<\/p>\n

Department of Pharmacology<\/p>\n

Vanderbilt University Medical Center<\/p>\n

23rd Avenue South at Pierce<\/p>\n

1215C MRB IV<\/p>\n

Nashville, TN 37232-6600<\/p>\n

Phone:\u00a0 615-343-4303<\/p>\n

Fax:\u00a0 (615) 936-6833<\/p>\n

E-mail: colleen.niswender@vanderbilt.edu<\/a><\/p>\n

EDUCATION<\/u><\/strong><\/p>\n

1986-1987\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0 Undergraduate, University of Akron, Akron, Ohio<\/p>\n

1987-1991\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/strong>Undergraduate, University of Toledo, Toledo, Ohio<\/p>\n

1991\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 B.S., Pharmacy with Honors in Pharmacology, University of Toledo,\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Toledo, Ohio<\/p>\n

1991-1996\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Graduate Student, Pharmacology, Vanderbilt University<\/p>\n

1996\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Ph.D., Pharmacology, Vanderbilt University<\/p>\n

PROFESSIONAL TRAINING AND EXPERIENCE<\/u><\/strong><\/p>\n

1996-1998\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Postdoctoral Fellow, Pharmacology, Vanderbilt University<\/p>\n

1998-2003\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Senior Fellow, Pharmacology, University of Washington<\/p>\n

2003-2004\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Acting Instructor, Pharmacology, University of Washington<\/p>\n

2004-2009\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Research Assistant Professor, Pharmacology, Vanderbilt\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0University,\u00a0Director, Molecular Pharmacology, Vanderbilt Program\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0in Drug Discovery<\/p>\n

2009-2017\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Research Associate Professor, Pharmacology, Vanderbilt\u00a0\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0University, Director, Molecular Pharmacology, Vanderbilt Center for\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Neuroscience Drug Discovery<\/p>\n

2017-present\u00a0 \u00a0 \u00a0\u00a0Research Professor, Pharmacology, Vanderbilt\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0University, Director, Molecular Pharmacology, Vanderbilt Center for\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Neuroscience Drug Discovery<\/p>\n

AWARDS AND HONORS<\/u><\/strong><\/p>\n

1991\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Valedictorian, College of Pharmacy<\/p>\n

1991\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Phi Kappa Phi Graduate Fellowship<\/p>\n

1991\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 AAPS-AFPE Gateway Scholarship<\/p>\n

1991\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The Merck-Sharp and Dohme Award in Medicinal Chemistry<\/p>\n

1991\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The Upjohn Award in Pharmacology<\/p>\n

1991\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The SmithKline Beechem Award in Clinical Pharmacy<\/p>\n

1993\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 First Place, Vanderbilt University Graduate Student Research Day<\/p>\n

1994\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 First Place, Vanderbilt University Graduate Student Research Day<\/p>\n

1995\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Grass Foundation Fellowship to attend \u201cNeurobiology of Human\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Neurological Disease: Mechanisms of Neurodegeneration\u201d, Cold\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Spring Harbor Laboratory<\/p>\n

2000\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Travel award for abstract submitted to \u201cObesity and the Regulation\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 of Energy Homeostasis\u201d, Keystone Symposium, Taos, NM<\/p>\n

PROFESSIONAL MEMBERSHIPS<\/u><\/strong><\/p>\n

1991-present\u00a0\u00a0 \u00a0\u00a0 Phi Kappa Phi<\/p>\n

2006-present\u00a0 \u00a0 \u00a0 Society for Neuroscience<\/p>\n

2007-present\u00a0\u00a0\u00a0\u00a0\u00a0 American Society for Pharmacology and Experimental\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Therapeutics<\/p>\n

RESEARCH SUPPORT-CURRENT (as of 1\/18\/2018)<\/u><\/strong><\/p>\n

1R01 MH108498-01 (Niswender C\/Lindsley C)\u00a0 12\/10\/2015-11\/30\/2018\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/strong>NIMH\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0$1,498,134, Total Project<\/strong><\/p>\n

Development of an mGlu2\/4 <\/sub>heterodimer-selective allosteric modulator. <\/strong>We propose that heterodimerization may underlie a divergence in in vivo<\/em> pharmacological profiles that we have observed with various mGlu4<\/sub> positive allosteric modulators that either do or do not potentiate the activity of mGlu2\/4<\/sub> heterodimers. We will chemically optimize small molecules with selectivity for mGlu2\/4 <\/sub>heteromers over mGlu2<\/sub> or mGlu4<\/sub> homomeric receptors.<\/p>\n

1R01MH110389-01 (Niswender C\/Lindsley C)\u00a0 \u00a0 \u00a007\/01\/2016-06\/30\/209\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/strong>NIMH\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 $1,714,670 Total Project<\/strong><\/p>\n

Optimization of a Metabotropic Glutamate Receptor 7 Positive Allosteric Modulator.\u00a0<\/strong>We propose to perform a chemical optimization campaign to develop mGlu7<\/sub> PAMs with enhanced specificity and pharmacokinetic properties and to use deficits in Mecp2-deficient mice to profile native tissue and in vivo activity of optimized compounds, with the goal of developing a highly selective mGlu7<\/sub> PAM to support continued exploration of the biology and therapeutic potential of this important receptor.<\/p>\n

PR160102 (Niswender C)\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a008\/01\/2017-07\/31\/2020\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 <\/strong>Department of Defense\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 $1,875,949, Total Project\u00a0\u00a0 <\/strong><\/p>\n

The Role of Metabotropic Glutamate Receptor 7 in the Etiology and Treatment of Rett Syndrome. <\/strong>This grant will examine the role of mGlu7<\/sub> in Rett syndrome by profiling mGlu7<\/sub> knockout mice, crossing mice with various mGlu7<\/sub> expression levels with Mecp2-deficient animals, and developing new mGlu7<\/sub>\u00a0negative\u00a0allosteric modulator probes.<\/p>\n

\u00a0<\/strong>3503\u00a0 (Niswender, C)\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a004\/01\/2017-03\/31\/2019\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/strong>Rettsyndrome.org\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0$150,000, Total Project\u00a0\u00a0\u00a0\u00a0\u00a0 <\/strong><\/p>\n

Exploration of Metabotropic Glutamate Receptor 3 as a Target for MeCP2-Related Disorders.\u00a0<\/strong>This grant proposes to determine if mGlu3<\/sub> is a new target that can be modulated with small molecules for therapeutic benefit in models of MeCP2-related disorders.<\/p>\n

\u00a0<\/strong>3511 (Niswender, C)\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 04\/01\/2018-03\/31\/2020\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/strong>Rettsyndrome.org\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0$150,000, Total Project\u00a0\u00a0\u00a0\u00a0\u00a0<\/strong><\/p>\n

Tailoring Gene Replacement Therapy for MECP2-Related Disorders.\u00a0<\/strong>This grant proposes to determine if mGlu3<\/sub>\u00a0is a new target that can be modulated with small molecules for therapeutic benefit in models of MeCP2-related disorders.<\/p>\n

 <\/p>\n

RESEARCH SUPPORT-COMPLETED (as of 1\/18\/2018)<\/u><\/strong><\/p>\n

Predoctoral\/Postdoctoral Awards<\/strong><\/p>\n

1994-1996\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Pharmaceutical Research and Manufacturers of America\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Foundation, Predoctoral Award in Pharmacology<\/p>\n

1997-1998\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Pharmaceutical Research and Manufacturers of America\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Foundation \u00a0Postdoctoral Award in Pharmacology<\/p>\n

1999-2000\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Fellow, Neurobiology and Behavior Training Grant, University\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0of\u00a0 Washington<\/p>\n

2000-2003\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Fellow, National Service Research Award, NIDDK<\/p>\n

03\/1\/03-02\/28\/04 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 University of Washington Diabetes and Endocrinology\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Research Center, Pilot and Feasibility Award<\/p>\n

 <\/p>\n

1 R03 MH076398-01 <\/strong>(Niswender, C)\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 08\/1\/05-07\/31\/06\u00a0 \u00a0 \u00a0 \u00a0<\/strong>NIH\/NIMH\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 $3,000 plus HTS<\/strong><\/p>\n

Measurement of GPCR-Mediated Thallium Flux through GIRK.\u00a0 <\/strong>This grant provided access to high-throughput screening (HTS) through the\u00a0Molecular Libraries Screening Center Network to search for modulators of the alpha 2C receptor.<\/p>\n

1R21NS053536-01\/1R21NS053536-01S1 (Niswender, C) 09\/30\/05-02\/28\/08\u00a0 <\/strong>\u00a0 \u00a0 \u00a0 \u00a0 <\/strong>NIH\/NIMH\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 <\/strong>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0$125,000 plus $25,000\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Supplement\u00a0<\/strong><\/p>\n

A Direct Assay for HTS of Gi\/o-linked GPCRs: mGluR7 as the Prototype<\/strong>.\u00a0This grant funded assay development to design an HTS-compatible assay to search for novel modulators of metabotropic glutamate receptor 7.<\/p>\n

1X01 MH077607-01 (Niswender, C)\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 <\/strong>02\/01\/06-01\/31\/07\u00a0 NIH\/NIMH\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 HTS funding<\/strong><\/p>\n

Discovery of novel allosteric agonists of the M4 muscarinic receptor.\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 <\/strong>This grant provided access to high-throughput screening (HTS) through the\u00a0Molecular Libraries Screening Center Network to search for modulators of the M4 muscarinic receptor.<\/p>\n

1R01 (Niswender, C)\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a002\/01\/04-11\/30\/09\u00a0 \u00a0 <\/strong>NIH\/NINDS<\/strong>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0$1,165,000 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 <\/strong><\/p>\n

Metabotropic Glutamate Receptors in Basal Ganglia.<\/strong>\u00a0 This grant examined the role of group III metabotropic glutamate receptors in modulating circuitry in the basal ganglia as novel treatments for Parkinson’s disease and other movement disorders. Grant transferred from P. Jeffrey Conn in final year of funding.<\/p>\n

LEAPS Award (Conn, PJ)\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a001\/01\/07-10\/30\/11\u00a0 <\/strong>Michael J. Fox Foundation\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0$3,609,000\u00a0 <\/strong><\/p>\n

Discovery of novel allosteric modulators of mGluR4 for treatment of Parkinson\u2019s disease<\/strong>.\u00a0 This grant was a lead optimization program to develop an mGlu4 positive allosteric modulator for the treatment of Parkinson’s disease. Role: Biology Project Team Leader<\/p>\n

Basic Research Award (Niswender, CM)\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 01\/01\/12-12\/31\/13\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 <\/strong>International Rett Syndrome Foundation\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0$100,000\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/strong><\/p>\n

Metabotropic Glutamate Receptor 7: a Novel Therapeutic Candidate for Rett Syndrome.<\/strong> This grant examined the regulation of mGlu7<\/sub> levels in the context of MeCP2 loss and provided the basis for new grants to develop novel allosteric modulators for MeCP2-based disorders.<\/p>\n

R21 NS078262 (Niswender, CM)\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 04\/01\/12-03\/13\/14\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 <\/strong>NIH\/NINDS\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/strong>$420,809, Total Project\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0Metabotropic Glutamate Receptors in the Basal Ganglia. The goals of this grant were to test the hypothesis that metabotropic glutamate receptor 8 is a novel target in Parkinson\u2019s disease. The grant involved a combination of molecular pharmacology, electrophysiology, and in vivo behavioral profiling.<\/p>\n

1UH2 NS099066-01 (Niswender, CM)\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 09\/01\/2016-09\/29\/2021\u00a0 \u00a0 <\/strong>NIH \/NINDS\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 <\/strong>\u00a0 $124,768, Total Project\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Development of VU0652957 for the treatment of Parkinson’s disease (PD).\u00a0<\/strong>We propose to utilize the Blueprint Neurotherapeutics Network (BPN) to advance VU0652957 through Investigational New Drug (IND)-enabling studies in preparation for clinical studies in PD patients. This is a development grant to advance an mGlu4<\/sub> positive allosteric modulator into clinical development for Parkinson\u2019s disease. Project ended due to lack of exposure required for efficacy in a nonhuman primate model of Parkinson\u2019s disease.<\/em><\/p>\n

5R21 MH102548-02 (Niswender, CM)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 08\/01\/2014-07\/31\/2017\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/strong><\/p>\n

NIMH\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 $431,476, Total Project<\/strong><\/p>\n

Metabotropic Glutamate Receptor Regulation in MeCP2-Related Disorders. <\/strong><\/p>\n

Based on dramatic decreases in mGlu7<\/sub> levels seen in mice that model Rett syndrome, we propose to test the hypothesis that mGlu7<\/sub> levels are conversely increased in an MECP2<\/em> Duplication mouse model, further substantiating a role for MeCP2 in mGlu7<\/sub> gene regulation. Additionally, we will test the hypotheses that modulation of mGlu7<\/sub> activity using pharmacological tools will normalize synaptic plasticity and behavioral deficits in mice under- and overexpressing MeCP2.<\/p>\n

 <\/p>\n

8766 <\/strong>(Niswender, C)\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a003\/01\/2014-08\/28\/2017\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 <\/strong>Autism Speaks\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0$449,996, Total Project<\/strong><\/p>\n

Temporal Divergence of Hypoconnectivity and Excitotoxicity in Rett Syndrome. <\/strong>The goals of these studies are to build upon our preliminary data showing that mGlu5<\/sub> PAMs reduce symptom severity and phenotypes in RS mice when administered in advanced disease states. We will also assess the liability for PAMs to elicit adverse consequences when administered early in disease due to temporal changes in glutamatergic transmission. Furthermore, we will determine whether mGlu5<\/sub> NAMs can temper excitotoxicity and prevent synapse loss when administered to young RS mice, thereby reducing the impact of developmental regression on RS phenotypes.<\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

INTRAMURAL AND EXTRAMURAL ACTIVITIES<\/u><\/strong><\/p>\n

\u00a0<\/u><\/p>\n

2006<\/u><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

–<\/strong>Grant reviewer, Melanoma Research Foundation<\/p>\n

-Manuscript reviewer, Journal of Neurochemistry<\/p>\n

-Paper discussion leader for Interdisciplinary Graduate Program Core Course. Kim et al., 2001, JBC. The role of phosphorylation in DI dopamine receptor desensitization.<\/p>\n

 <\/p>\n

2007<\/u><\/p>\n

\u00a0<\/u><\/p>\n

-Manuscript reviewer, Molecular Pharmacology<\/p>\n

-Lecturer in Neuroscience 345 Course.\u00a0 Neuromodulation and metabotropic glutamate receptors.<\/p>\n

-Paper discussion leader in Neuroscience 345 Course. Sansig et al., 2001, J. Neuroscience. Increased seizure susceptibility in mice lacking metabotropic glutamate receptor 7.<\/p>\n

-Paper discussion leader for Interdisciplinary Graduate Program Core Course. Ross et al., 1978 JBC. Reconstitution of hormone-sensitive adenylate cyclase activity with resolved components of the enzyme.<\/p>\n

 <\/p>\n

2008<\/u><\/p>\n

\u00a0<\/u><\/p>\n

-Manuscript reviewer, Neuropharmacology<\/p>\n

-Paper discussion leader for Interdisciplinary Graduate Program Core Course. Kim et al., 2001, JBC. The role of phosphorylation in DI dopamine receptor desensitization.<\/p>\n

-Lecturer in Neuroscience 345 Course. Neuromodulation and metabotropic glutamate receptors.<\/p>\n

-Paper discussion leader in Neuroscience 345 Course. Volk et al., 2007, J. Neuroscience. Multiple Gq coupled receptors converge on a common protein synthesis-dependent long term-depression that is affected in fragile X mental retardation.<\/p>\n

\u00a0<\/u><\/p>\n

2009<\/u><\/p>\n

\u00a0<\/u><\/p>\n

Grant reviewer, Michael J. Fox Foundation<\/p>\n

Manuscript reviewer, Molecular Pharmacology<\/p>\n

Manuscript reviewer, ACS Chemical Neuroscience<\/p>\n

Manuscript reviewer, Journal of Neuroscience<\/p>\n

Manuscript reviewer, J Pharmacol Exp Therapeutics<\/p>\n

Manuscript reviewer, British Journal of Pharmacology<\/p>\n

 <\/p>\n

2010<\/u><\/p>\n

Manuscript reviewer, British Journal of Pharmacology<\/p>\n

Manuscript reviewer, Molecular Pharmacology<\/p>\n

Manuscript reviewer, Neuropharmacology<\/p>\n

Manuscript reviewer, Neuroscience<\/p>\n

 <\/p>\n

2011<\/u><\/p>\n

Manuscript reviewer, Journal of Biological Chemistry<\/p>\n

Manuscript reviewer, The International Journal of Neuropsychopharmacology<\/p>\n

Manuscript reviewer, Nature Protocols<\/p>\n

Manuscript reviewer, Proceedings of the National Academy of Sciences<\/p>\n

 <\/p>\n

2012<\/u><\/p>\n

Grant reviewer, Multiple Sclerosis Fast Forward Foundation<\/p>\n

Manuscript reviewer, Expert Opinion on Drug Discovery<\/p>\n

Manuscript reviewer, Neuropharmacology<\/p>\n

Manuscript reviewer, Pharmacology, Biochemistry, and Behavior<\/p>\n

Manuscript reviewer, Molecular Pharmacology<\/p>\n

Manuscript reviewer, ACS Chemical Neuroscience<\/p>\n

Guest lecturer, Drug Discovery Course. \u201cmGlu4<\/sub> positive allosteric modulators for the treatment of CNS disorders\u201d. Vanderbilt University, October 17, 2012.<\/p>\n

\u00a0<\/u><\/p>\n

2013<\/u><\/p>\n

-Manuscript reviewer, Journal of Neurochemistry<\/p>\n

-Manuscript reviewer, Neuropharmacology<\/p>\n

-Grant reviewer, Michael J. Fox Foundation<\/p>\n

-Grant reviewer, Pilot and Feasibility Awards program, Vanderbilt University for Obesity and Metabolism<\/p>\n

-Grant reviewer, NIH EUREKA program<\/p>\n

-Special Guest Editor, Neuropharmacology, \u201cThe Synaptic Basis of Neurodegeneration\u201d<\/p>\n

-Manuscript reviewer, Journal of Neurochemistry<\/p>\n

-Guest lecturer, Neuroscience 235 Course. \u201cDrug Discovery in Academia: mGlu4 positive allosteric modulators for the treatment of CNS disorders\u201d. Vanderbilt University, March 14, 2013.<\/p>\n

-Guest lecturer, Drug Discovery Course. \u201cmGlu4<\/sub> positive allosteric modulators for the treatment of CNS disorders\u201d. Vanderbilt University, November 6, 2013.<\/p>\n

-Co-organizer, Academic Drug Discovery Conference, Nashville TN, October 9-11, 2013.<\/p>\n

 <\/p>\n

2014<\/u><\/p>\n

-Manuscript reviewer, Molecular Pharmacology<\/p>\n

-Manuscript reviewer, Neuropharmacology<\/p>\n

-Manuscript reviewer, Journal of Pharmacology and Experimental Therapeutics<\/p>\n

-Grant reviewer, Trailblazer Award, Autism Speaks<\/p>\n

-Guest lecturer, Neuroscience 235 Course. \u201cDrug Discovery in Academia: mGlu4 positive allosteric modulators for the treatment of CNS disorders\u201d. Vanderbilt University, March 11, 2014.<\/p>\n

-Grant reviewer, IWT<\/p>\n

-Grant reviews, Meixner Postdoctoral Fellowship Program, Autism Speaks<\/p>\n

-Guest lecturer, Drug Discovery Course. \u201cmGlu4<\/sub> positive allosteric modulators for the treatment of CNS disorders\u201d. Vanderbilt University, October, 2014.<\/p>\n

 <\/p>\n

2015<\/p>\n

-Manuscript reviewer, Neuropharmacology<\/p>\n

– Guest lecturer, Neuroscience 235 Course. \u201cDrug Discovery in Academia: mGlu4 positive allosteric modulators for the treatment of CNS disorders\u201d. Vanderbilt University, February 24, 2015.<\/p>\n

-Grant reviewer, Meixner Postdoctoral Fellowship Program, Autism Speaks<\/p>\n

-Guest lecturer, Drug Discovery Course. \u201cmGlu4<\/sub> positive allosteric modulators for the treatment of CNS disorders\u201d. Vanderbilt University, October, 2015.<\/p>\n

 <\/p>\n

2016<\/p>\n

-Manuscript reviewer, Neuropharmacology<\/p>\n

-Manuscript reviewer, Frontiers in Neural Circuits<\/p>\n

– Guest lecturer, Neuroscience 235 Course. \u201cDrug Discovery in Academia: mGlu4 positive allosteric modulators for the treatment of CNS disorders\u201d. Vanderbilt University, February 24, 2015.<\/p>\n

-Guest lecturer, Modern Drug Discovery, \u201cmGlu4 positive allosteric modulators for the<\/p>\n

-Grant reviewer, Meixner Postdoctoral Fellowship Program, Autism Speaks<\/p>\n

-Member, VICTR \u201cDrug Repurposing Think Tank\u201d<\/p>\n

 <\/p>\n

2017<\/p>\n

-Manuscript reviewer, Neuropharmacology<\/p>\n

-Introduction to the Vanderbilt Center for Neuroscience Drug Discovery: Case Study in Rett Syndrome, MSTP Second Look Day, Vanderbilt University, April 7, 2017.<\/p>\n

-Co-chair of Autism Spectrum Disorders Speaking Session, 9th<\/sup> International Meeting on Metabotropic Glutamate Receptors<\/p>\n

 <\/p>\n

\u00a0<\/u><\/strong><\/p>\n


\n<\/u><\/strong><\/p>\n

STUDENTS\/POSTDOCS DIRECTLY SUPERVISED\/THESIS COMMITTEES<\/u><\/strong><\/p>\n

 <\/p>\n

Caroline Kim\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 VUMC Emphasis Program for Medical Students, 2007-2008. \u2018Investigation of type III metabotropic glutamate receptor potentiators using a novel HTS assay using thallium flux through GIRK channels\u201d. Current position, General Surgeon at Houston Methodist, San Jacinto.<\/p>\n

 <\/p>\n

Alexander Kane \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Vanderbilt University undergraduate. \u201cThe in vivo<\/em> characterization of TBPB, a novel allosteric agonist of M1 muscarinic receptors: Implications for the role of M1 muscarinic receptors in treatment of schizophrenia\u201d. Honors thesis, May, 2008.<\/p>\n

 <\/p>\n

Shen Yin \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Vanderbilt University pharmacology graduate student. Co-mentor, graduated September, 2013. \u201cAllosteric modulation of metabotropic glutamate receptors\u201d. Current position, Associate Clinical Scientist, Genentech.<\/p>\n

 <\/p>\n

Olivia Veatch\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Vanderbilt University genetics graduate student. Thesis committee member, graduated August, 2013. \u201cIdentifying biological pathways implicated in defined subgroups of phenotypic expression for autism spectrum disorders.\u201d Current position, Research Instructor in Neurology, Vanderbilt Kennedy Center.<\/p>\n

 <\/p>\n

Frank Byers\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Vanderbilt University Masters in Laboratory Investigation student, thesis committee, graduated May 2014.<\/p>\n

 <\/p>\n

Rebecca Klar Senter \u00a0\u00a0\u00a0 Vanderbilt University pharmacology graduate student, Co-mentor. Awarded Weatherstone predoctoral fellowship from Autism Speaks 7\/1\/2014, graduation 7\/14\/2015. Current position, Scientist, Flexion Therapeutics.<\/p>\n

 <\/p>\n

Rachel Crouch\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Vanderbilt University pharmacology graduate student, co-chair of thesis committee. Graduation 11\/2016. Current position, Postdoctoral fellow, VCNDD.<\/p>\n

 <\/p>\n

Thomas Utley\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Vanderbilt University pharmacology postdoc. Current position, Licensing Agent, Vanderbilt Technology Transfer office.<\/p>\n

 <\/p>\n

Julie Roper-Field \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Vanderbilt University pharmacology postdoc. Current position, Project Manager, VICTR and CTSA Consortium Coordinating Center, Vanderbilt University Medical Center.<\/p>\n

 <\/p>\n

Nidhi Jalan-Sakrikar\u00a0\u00a0\u00a0\u00a0 Vanderbilt University pharmacology postdoc (2012-2014), Current position, postdoctoral fellow at Mayo Clinic.<\/p>\n

 <\/p>\n

Rocco Gogliotti\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Vanderbilt University pharmacology postdoc, joined lab in 2012, awarded postdoctoral fellowship from International Rett Syndrome Foundation, 2014. Awarded BBRF fellowship in 2016 (current).<\/p>\n

 <\/p>\n

Nicole Fisher\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Vanderbilt University Interdisciplinary Graduate Student, joined lab Spring of 2015, awarded Pharmacology Training grant slot, 2015 (current).<\/p>\n

 <\/p>\n

Branden Stansley\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Vanderbilt University Pharmacology Postdoctoral Fellow, joined lab Spring of 2015, awarded T32 postdoctoral training award and an F32 NRSA, June 2016 (current).<\/p>\n

 <\/p>\n

Sheryl Vermudez\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Vanderbilt University Interdisciplinary Graduate Student, joined lab Spring of 2017 (current).<\/p>\n

 <\/p>\n

Annah Moore\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Vanderbilt University Interdisciplinary Graduate Student, joined Sweatt Lab in Spring of 2017, co-mentor (current).<\/p>\n

 <\/p>\n

Christian Marks\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Vanderbilt University Molecular Physiology and Biophysics Graduate Student, thesis committee (current).<\/p>\n

 <\/p>\n

Sean Moran\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Vanderbilt Neuroscience Graduate Student, thesis committee (current).<\/p>\n

 <\/p>\n

Nick Harris\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Vanderbilt University Molecular Physiology and Biophysics MD\/PhD Student, thesis committee (current).<\/p>\n

 <\/p>\n

Mabel Seto\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Vanderbilt University Interdisciplinary Graduate Student, thesis committee (current).<\/p>\n

 <\/p>\n

Christopher Hofmann\u00a0\u00a0 Vanderbilt University Interdisciplinary Graduate Student, thesis committee (current).<\/p>\n

 <\/p>\n

 <\/p>\n

Rotation students<\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

Yerai Oliveres (2004), Alex Nakenoff (2009), Michael Nedelcovych (2009), Shen Yin (2009) Sahana Naganhushan Kalburgi (2014), Aparna Shekar (2014), Nicole Fisher (2015), Francis Prael (2015), Nathan Winters (2017), Annah Moore (2017), Sheryl Vermudez (2017), Sarah Naguib (2017)<\/p>\n

 <\/p>\n

 <\/p>\n


\n<\/u><\/strong><\/p>\n

PRESENTATIONS<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

1998<\/u><\/p>\n

 <\/p>\n

-Identification and Functional Characterization of Edited Human Serotonin 2c Receptor Isoforms. 4th<\/sup> IUPHAR Satellite Meeting on Serotonin. October 1998.<\/p>\n

\u00a0<\/u><\/p>\n

2006 <\/u><\/p>\n

 <\/p>\n

-High Throughput Screening and Medicinal Chemistry at Vanderbilt in Support of Drug Discovery for Muscarinic Receptor Ligands. Vanderbilt Institute for Chemical Biology Retreat.<\/p>\n

 <\/p>\n

-Allosteric modulation of metabotropic glutamate receptor 5, M1, and M4 muscarinic receptors: potential therapeutic directions for schizophrenia. 27th<\/sup> Annual Meeting of the Southeastern Pharmacology Society. November 2006.<\/p>\n

\u00a0<\/u><\/p>\n

\u00a0<\/u><\/p>\n

2007<\/u><\/p>\n

\u00a0<\/u><\/p>\n

-High Throughput Screening and Medicinal Chemistry at Vanderbilt: The search for Allosteric Ligands of the M1 and M4 Muscarinic Receptors. HTS Users Group Meeting, Vanderbilt University. March, 2007<\/p>\n

\u00a0<\/u><\/p>\n

2008 <\/u><\/p>\n

\u00a0<\/u><\/p>\n

-Allosteric modulation of mGluR4 as a novel therapeutic direction for the treatment of Parkinson\u2019s disease. American Society for Biochemistry and Molecular Biology, Experimental Biology, San Diego, CA. April, 2008.<\/p>\n

 <\/p>\n

-Allosteric modulation of GCPRs as a novel therapeutic direction for the treatment of CNS disorders. American Society of Pharmacology and Experimental Therapeutics, Experimental Biology, San Diego, CA, April. 2008.<\/p>\n

 <\/p>\n

-Allosteric modulation of mGluR4 as a novel therapeutic direction for the treatment of Parkinson\u2019s disease. Keystone Symposia; G Protein Coupled Receptors: New Insights in Functional Regulation and Clinical Application, Killarney, Ireland. May, 2008.<\/p>\n

 <\/p>\n

-Allosteric modulation of mGluR4: a novel therapeutic direction for the treatment of Parkinson\u2019s disease.\u00a0 6th<\/sup> International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy. September, 2008.<\/p>\n

 <\/p>\n

2009<\/u><\/p>\n

\u00a0<\/u><\/p>\n

-The development of positive allosteric modulators of mGluR4 for the treatment of Parkinson\u2019s disease. WFN World Congress on Parkinson\u2019s Disease and Related Disorders. Miami, FL. December, 2009.<\/p>\n

2010<\/u><\/p>\n

 <\/p>\n

-The development of positive allosteric modulators of mGluR4 for the treatment of Parkinson\u2019s disease\u2014Parkinson\u2019s Disease Case Study. 4th Annual Drug Discovery for Neurodegeneration Conference. Houston, TX. February, 2010.<\/p>\n

 <\/p>\n

-HTS results from academia: discovery of allosteric modulators of mGluR4 and 5. Metabotropic Glutamate Receptors: Translation from Discovery to Clinical Trials. The New York Academy of Sciences. New York, NY. February, 2010.<\/p>\n

 <\/p>\n

-Functionally selective and context dependent pharmacology of GPCR allosteric modulators.\u00a0 Pharmacology drive assays for GPCRs and ion channels. Ninth Annual World Pharmaceutical Congress. Philadelphia, PA, June, 2010.<\/p>\n

 <\/p>\n

-Novel ion channel-based assays: detecting and characterizing 7TM receptor modulators. Pharmacology drive assays for GPCRs and ion channels. Ninth Annual World Pharmaceutical Congress. Philadelphia, PA, June, 2010.<\/p>\n

 <\/p>\n

-The Development of Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4. Allosteric Modulator Drug Discovery Congress, San Diego, CA, November, 2010.<\/p>\n

 <\/p>\n

2011<\/u><\/p>\n

 <\/p>\n

-mGlu4 receptor positive allosteric modulator development for the treatment of CNS disorders. 7th<\/sup> International Meeting on Metabotropic Glutamate Receptors, Taormina, Italy. October, 2011.<\/p>\n

 <\/p>\n

\u00a0<\/u><\/p>\n

2012<\/u><\/p>\n

 <\/p>\n

-mGlu4 positive allosteric modulators for the treatment of CNS disorders. 45th<\/sup> Annual Winter Conference on Brain Research. Snowbird, Utah, January.<\/p>\n

 <\/p>\n

2013<\/u><\/p>\n

\u00a0<\/u><\/p>\n

-mGlu4 positive allosteric modulators for the treatment of CNS disorders. Guest presentation to Vanderbilt Parkinson\u2019s Disease Advisory Board, Vanderbilt University, April 19, 2013.<\/p>\n

 <\/p>\n

-Metabotropic glutamate receptor 7: a novel therapeutic target for MeCP2-related disorders. Vanderbilt University Rett Syndrome Symposium, October 16, 2013.<\/p>\n

 <\/p>\n

2014<\/u><\/p>\n

-Metabotropic glutamate receptor potentiation as a therapeutic direction in Rett syndrome. Invited talk, International Rett Syndrome Foundation meeting, June 25, 2014.<\/p>\n

 <\/p>\n

-Metabotropic glutamate receptor 7 (mGlu7<\/sub>): a novel target for the treatment of Rett syndrome. Invited talk, 8th<\/sup> International Meeting on Metabotropic Glutamate Receptors, October 2, 2014.<\/p>\n

 <\/p>\n

-Metabotropic glutamate receptor 7 (mGlu7<\/sub>): a novel target for the treatment of Rett syndrome. Invited talk, Multimodal Interventions in IDD from Drug Discovery to Clinical Trials, Vanderbilt Kennedy Center, October 22, 2014.<\/p>\n

 <\/p>\n

2015<\/u><\/p>\n

 <\/p>\n

-Metabotropic glutamate receptor 7: a new therapeutic target for both Rett and MECP2 <\/em>Duplication syndromes. Invited talk, MECP2 Duplication Conference, Houston TX, Sept 2015.<\/p>\n

 <\/p>\n

2016<\/u><\/p>\n

\u00a0<\/u><\/p>\n

-Metabotropic Glutamate Receptor 4 Positive Allosteric Modulators for Parkinson\u2019s Disease: Impact of Receptor Heterodimerization. CNS Diseases World Summit. Boston, MA, Sept 12, 2016.<\/p>\n

 <\/p>\n

2017<\/u><\/p>\n

 <\/p>\n

-Therapeutic Potential of mGlu7 in Neurodevelopmental Disorders. Invited Speaker, 9th<\/sup> International Meeting on Metabotropic Glutamate receptors. Taormina, Italy, October 2017.<\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

\u00a0<\/u><\/strong><\/p>\n

ISSUED PATENTS<\/u><\/strong><\/p>\n

 <\/p>\n

    \n
  1. Benzamide mGluR5 Positive Allosteric Modulators and Methods of Making and Using Same. Patent 8,853,392. Filed 6\/3\/2008. Issued patent, USA.<\/li>\n<\/ol>\n

     <\/p>\n

      \n
    1. Benzamide mGluR5 Positive Allosteric Modulators and Methods of Making and Using Same. Patent 5622568. Filed 12\/2\/2009. Issued patent, Japan.<\/li>\n<\/ol>\n

       <\/p>\n

        \n
      1. Substituted Dioxopiperidines and Dioxopyrrolidines as mGluR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction. Patent 8,759,377. Filed 11\/23\/2010. Issued patent, USA.<\/li>\n<\/ol>\n

         <\/p>\n

          \n
        1. Alkyl-3-((2-Amidoethyl)Amino)-8-Azabicyclo[3.2.1]Octane-8-Carboxylate Analogs as M1 Allosteric Agonists and Methods of Making and Using Same. Patent 8,697,691. Filed 12\/21\/2010. Issued patent, USA.<\/li>\n<\/ol>\n

           <\/p>\n

            \n
          1. Substituted 1,1,3,1-Tetraoxidobenzo{D} {1,3,2}Dithiazoles as mGluR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction. Patent 8,658,650. Filed 1\/28\/2011. Issued patent, USA.<\/li>\n<\/ol>\n

             <\/p>\n

              \n
            1. Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as mGluR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction. Patent zl 201180017221.4. Filed 2\/11\/2011. Issued patent, China.<\/li>\n<\/ol>\n

               <\/p>\n

                \n
              1. Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as mGluR4 Allosteric Potentiators, Compounds, and Methods of Treating Neurological Dysfunction. Patent 2012\/06416. Filed 2\/11\/2011. Issued patent, South Africa.<\/li>\n<\/ol>\n

                 <\/p>\n

                  \n
                1. Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as mGluR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction. Patent 9,163,015. Filed 2\/11\/2011. Issued patent, USA.<\/li>\n<\/ol>\n

                   <\/p>\n

                    \n
                  1. Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as mGluR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction. Patent 2011215638. Filed 2\/11\/2011. Issued patent, Australia.<\/li>\n<\/ol>\n

                     <\/p>\n

                      \n
                    1. Pyrazolopyridine, Pyrazolopyrazine, Pyrazolothiophene and Pyrazolothiazole Compounds as mGluR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction. Patent 9,108,963. Filed 8\/13\/2012. Issued patent, USA.<\/li>\n<\/ol>\n

                       <\/p>\n

                        \n
                      1. mGluR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction. Filed 4\/23\/2012. Patent 9,180,192. Issued patent, USA.<\/li>\n<\/ol>\n

                         <\/p>\n

                          \n
                        1. mGluR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction. Patent 8,779,157. Filed 6\/12\/2012. Issued patent, USA.<\/li>\n<\/ol>\n

                           <\/p>\n

                            \n
                          1. Aryl and Heteroaryl Sulfones as mGluR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction. Patent 8,912,336. Filed 6\/12\/2012. Issued patent, USA.<\/li>\n<\/ol>\n

                             <\/p>\n

                              \n
                            1. Benzisoxazoles and Azabenzisoxazaoles as mGluR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction, Patent 8,916,584, Filed 8\/13\/2012. Issued patent, USA.<\/li>\n<\/ol>\n

                               <\/p>\n

                                \n
                              1. Heterocyclic Sulfone mGluR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction. Patent 9,192,603, Filed 11\/13\/2012. Issued patent, USA.<\/li>\n<\/ol>\n

                                 <\/p>\n


                                \n<\/u><\/strong><\/p>\n

                                ABSTRACTS<\/u><\/strong><\/p>\n

                                \u00a0<\/u><\/strong><\/p>\n

                                  \n
                                1. Burns, CM<\/strong>, Obermiller PS, Emeson RB.\u00a0 RNA editing of AMPA receptor subunit (GluR-B) mRNA.\u00a0, Society for Neuroscience Abstracts, 1993.<\/li>\n<\/ol>\n

                                   <\/p>\n

                                    \n
                                  1. Burns CM<\/strong>, Rueter SM, Emeson RB.\u00a0 Molecular mechanisms mediating the editing of glutamate receptor (GluR-B) RNA transcripts.\u00a0 Albany Conference, RNA Editing, 1994.<\/li>\n<\/ol>\n

                                     <\/p>\n

                                      \n
                                    1. Rueter, SM, Burns CM<\/strong> and Emeson RB. In vitro<\/em> editing of glutamate receptor (GluR-B) RNA transcripts. RNA Processing: Cold Spring Harbor Laboratory, 1995.<\/li>\n<\/ol>\n

                                      \u00a0<\/strong><\/p>\n

                                        \n
                                      1. Burns CM<\/strong>, Chu H, Rueter SM, Sanders-Bush E, Emeson RB. Identification and characterization of RNA editing within the serotonin 2C receptor. Society for Neuroscience Abstracts, 1996.<\/li>\n<\/ol>\n

                                         <\/p>\n

                                          \n
                                        1. Chu H, Burns C<\/strong>, Canton H, Emeson RB, Sanders-Bush E. Functional characterization of rat serotonin 5-HT2C <\/sub>receptor editing isoforms. Society for Neuroscience Abstracts, 1996.<\/li>\n<\/ol>\n

                                           <\/p>\n

                                            \n
                                          1. Rueter SM, Burns<\/strong> CM, Emeson RB. Characterization of AMPA receptor subunit (GluR-B) RNA editing in rat brain nuclear extracts. Society for Neuroscience Abstracts, 1996.<\/li>\n<\/ol>\n

                                            \u00a0<\/strong><\/p>\n

                                              \n
                                            1. Burns CM<\/strong>, Chu H, Rueter SM, Sanders-Bush E, Emeson RB. RNA editing of transcripts encoding the serotonin 2C receptor. EMBO workshop on RNA Editing, 1996.<\/li>\n<\/ol>\n

                                              \u00a0<\/strong><\/p>\n

                                                \n
                                              1. Burns CM<\/strong>, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E, Emeson RB. RNA editing of serotonin 2C receptor transcripts. RNA Society Meeting, 1997.<\/li>\n<\/ol>\n

                                                \u00a0<\/strong><\/p>\n

                                                  \n
                                                1. Niswender CM<\/strong>, Copeland S, Emeson RB and Sanders-Bush E. Identification and Functional Characterization of Edited Human Serotonin 2c Receptor Isoforms. 4th<\/sup> IUPHAR Satellite Meeting on Serotonin, 1998.<\/li>\n<\/ol>\n

                                                  \u00a0<\/strong><\/p>\n

                                                    \n
                                                  1. Niswender CM,<\/strong> Copeland SC, Dilley G., Meltzer HY, Overholser JC, Stockmeier CA, Emeson RB, Sanders-Bush E.\u00a0 RNA editing of human serotonin 2C receptor transcripts. Society for Neuroscience Abstracts,<\/li>\n<\/ol>\n

                                                     <\/p>\n

                                                      \n
                                                    1. Berg KA, Cropper JD, Niswender CM<\/strong>, Sanders-Bush E, Emeson RB Clarke WP. Activation of PLC and PLA2<\/sub> by h5-HT2C<\/sub> receptor RNA-edited isoforms. Society for Neuroscience Abstracts,<\/li>\n<\/ol>\n

                                                      \u00a0<\/strong><\/p>\n

                                                        \n
                                                      1. Niswender CM<\/strong>, McKnight GS. Cre recombinase-mediated expression of a constitutively active form of protein kinase A. Keystone Conference, Obesity and the Regulation of Energy Homeostasis, Taos, NM, 2001.<\/li>\n<\/ol>\n

                                                         <\/p>\n

                                                          \n
                                                        1. Willis BS, Niswender CM<\/strong>, McKnight GS. Cre recombinase-mediated expression of dominant-negative and constitutively active protein kinase A subunits. Society for Neuroscience Abstracts, 2001.<\/li>\n<\/ol>\n

                                                          \u00a0<\/strong><\/p>\n

                                                            \n
                                                          1. Niswender CM<\/strong>, Willis BS, Sweet IR, Wallen A, Thompson B, Wu C, Lange AJ, McKnight GS. Expression of a constitutively active PKA holoenzyme in the liver results in glucose intolerance and impaired glucose-stimulated insulin secretion in mice. Keystone Conference, Toward Understanding Islet Biology, Keystone, CO, 2003.<\/li>\n<\/ol>\n

                                                            \u00a0<\/strong><\/p>\n

                                                              \n
                                                            1. Niswender CM<\/strong>, Myers KA, Banko JL, Rodriguez AL, Edl J, Zhang Y, Shirey JK, Saleh SA, Weaver CD, Conn PJ. Identification of novel allosteric modulators of group III mGluRs: New tools for the study of synaptic transmission. 5th<\/sup> Meeting on Metabotropic Glutamate Receptors, Taormina, Italy, 2005.<\/li>\n<\/ol>\n

                                                               <\/p>\n

                                                                \n
                                                              1. Edl J, Rodriguez AL, Tamagnan G, Alagille D, Johnson RL, Niswender C<\/strong>, Myers K, Conn PJ. Characterization of structural analogs of a Group III mGluR agonist and mGluR4\/5 allosteric modulators. Society for Neuroscience Abstracts, 2005.<\/li>\n<\/ol>\n

                                                                 <\/p>\n

                                                                  \n
                                                                1. Myers KA, Niswender CM,<\/strong> Williams R, Edl J, Saleh S, Jones CK, Weaver CD, Orton D, Conn PJ. Characterization of novel allosteric antagonists of metabotropic glutamate receptor subtype 7. Society for Neuroscience Abstracts, 2006.<\/li>\n<\/ol>\n

                                                                   <\/p>\n

                                                                    \n
                                                                  1. Brady AE, Shirey JK, Rodriguez AL, Niswender CM<\/strong>, Weaver CD, Conn, PJ. A high throughput functional screen for the identification of selective allosteric ligands of the M1 mAChR. Society for Neuroscience Abstracts, 2006.<\/li>\n<\/ol>\n

                                                                     <\/p>\n

                                                                      \n
                                                                    1. Edl J, Banko JL, Myers KA, Niswender CM<\/strong>, Conn PJ. Developmental differences in group III mGluR regulation of synaptic transmission in area CAI of the rat hippocampus. Society for Neuroscience Abstracts, 2006.<\/li>\n<\/ol>\n

                                                                      \u00a0<\/strong><\/p>\n

                                                                        \n
                                                                      1. Niswender CM<\/strong>, Myers KA, Williams R, Ayala J, Luo Q, Saleh S, Jones CK, Weaver CD, Orton D, Conn PJ. Permissive antagonism induced by novel allosteric antagonists of metabotropic glutamate receptor 7. American College of Neuropsychopharmacology Abstracts, 2006.<\/li>\n<\/ol>\n

                                                                         <\/p>\n

                                                                          \n
                                                                        1. Conn PJ, Weaver CD, Niswender C<\/strong>, Brady A, Shirey J, Edl J. Discovery and characterization of novel allosteric modulators of GPCRs. American College of Neuropsychopharmacology Abstracts, 2006.<\/li>\n<\/ol>\n

                                                                          \u00a0<\/strong><\/p>\n

                                                                            \n
                                                                          1. Niswender CM<\/strong>, Jones CK, Weaver CD, Rodriguez AL, Chen Y, Shirey JK, Brady AE, Marlo JE, Luo Q, Xianzhang M, Williams L, Hammond AS, Myers KA, Orton D, Williams R, Days EL, Nalywajko NT, Williams, M, Conn PJ. Allosteric modulation of metabotropic glutamate receptor 5, M1 and M4 muscarinic receptors: potential therapeutic directions for schizophrenia. Southeastern Pharmacology Society Abstracts, 2006.<\/li>\n<\/ol>\n

                                                                            \u00a0<\/strong><\/p>\n

                                                                              \n
                                                                            1. Niswender CM<\/strong>, Weaver CD, Lindsley CW, Jones CK, Lewis M, Marlo JE, Shirey JK, Xiang Z, Brady AE, Orton D, Williams R, Rodriguez AL, Yin H, Days EL, Farmer C, Luo Q, Xianzhang M, Myers KA, Ayal JE, Nalywajko NT, Lorsen KA, Williams M, Conn PJ. High Throughput Screening, Medicinal Chemistry, Physiology, and Behavioral Pharmacology at Vanderbilt in Support of Drug Discovery for Targets Involved in CNS Disorders. 8th<\/sup> Annual Rett Syndrome Symposium, 2007.<\/li>\n<\/ol>\n

                                                                               <\/p>\n

                                                                                \n
                                                                              1. Bridges T, Jones C, Brady A, Marlo J, Rodriguez A, Niswender C<\/strong>, Williams R., Kim K., Sheffler D, Grier M, Weaver D, Conn PJ, Lindsley C. Novel allosteric modulation of the M1 muscarinic receptor: agonists and potentiators for the treatment of Alzheimer\u2019s disease and schizophrenia. ACS-CNS Medicinal Chemistry Conference, 2007.***<\/li>\n<\/ol>\n

                                                                                 <\/p>\n

                                                                                  \n
                                                                                1. Myers-Johnson KA, Niswender CM<\/strong>, Luo Q, Ayala JE, Rodriguez AL, Marlo JE, Days EL, Nalywajko NT, Lornsen KA, Williams M, Lewis M, Weaver CD, Conn PJ. Discovery, synthesis, and SAR of a series of novel positive allosteric modulators of metabotropic glutamate receptor subtype 4. Society for Neuroscience Abstracts, 2007.<\/li>\n<\/ol>\n

                                                                                   <\/p>\n

                                                                                    \n
                                                                                  1. Shirey, JK, Xiang Z,\u00a0 Orton D, Brady AE, Johnson KA, Williams R, Ayala JE, Rodriguez AL, Wess J Weaver CD, Niswender CM<\/strong>, Conn PJ. An allosteric potentiator suggests a role for M4<\/sub> muscarinic acetylcholine receptor (mAChR) in modulating excitatory hippocampal synaptic transmission. Experimental Biology\/American Society of Pharmacology and Therapeutics Abstracts, 2008.***<\/li>\n<\/ol>\n

                                                                                     <\/p>\n

                                                                                      \n
                                                                                    1. Bridges TM, Jones CK, Brady AE, Sheffler DJ, Marlo JE, Niswender CM<\/strong>, Williams R, Williams L, Mulder MJ, Lewis M, Daniels RN, Davis AA, Lah JJ, Levey AI, Weaver CD, Conn PJ, Lindsley CW. Discovery and characterization of novel highly-selective agonists and antagonists of mAChR1: In-vitro and in-vivo profiles relevant to Alzheimer\u2019s disease and schizophrenia. American Society of Pharmacology and Experimental Therapeutics Abstracts, 2008.<\/li>\n<\/ol>\n

                                                                                       <\/p>\n

                                                                                        \n
                                                                                      1. Bridges, TM, Jones CK, Brady AE, Shirey JK, Kennedy JP, Rodriguez AL, Niswender CM<\/strong>, Williams R, Orton D, Gentry PR, Williams L, Mulder M, Weaver CD, Conn PJ, Lindsley CW. Subtype-selective allosteric modulation of the M4 muscarinic acetylcholine receptor. American Chemical Society Meeting Abstracts, 2008.<\/li>\n<\/ol>\n

                                                                                         <\/p>\n

                                                                                          \n
                                                                                        1. Lewis M, Sheffler D, Williams R, Bridges TM, Kennedy PJ, Brogan JT, Mulder MJ, Williams L, Nalywajko NT, Niswender CM<\/strong>, Weaver CD, Conn PJ, Lindsley CW. The discovery and development of a highly selective and centrally active M1 antagonist. American Chemical Society Abstracts, 2008.<\/li>\n<\/ol>\n

                                                                                           <\/p>\n

                                                                                            \n
                                                                                          1. Days, E, Lewis M, Mi D, Luo Q, Dorset D, Bailey S, Farmer C, Niswender C<\/strong>, Conn, PJ, Weaver CD. Discovery of novel allosteric modulators of metabotropic glutamate receptor 8 (mGluR8) using thallium flux modulation in high throughput screening. Society for Biomolecular Screening Abstracts, 2008.***<\/li>\n<\/ol>\n

                                                                                             <\/p>\n

                                                                                              \n
                                                                                            1. Shirey, JK, Xiang Z,\u00a0 Orton D, Brady AE, Johnson KA, Williams R, Ayala JE, Rodriguez AL, Wess J Weaver CD, Niswender CM<\/strong>, Conn PJ. An allosteric potentiator of M4 muscarinic acetylcholine receptor (mAChR) modulates excitatory hippocampal synaptic transmission. Keystone Conference, G Protein Coupled Receptors: New Insights in Functional Regulation and Clinical Application, Killarney, Ireland, 2008.***<\/li>\n<\/ol>\n

                                                                                               <\/p>\n

                                                                                                \n
                                                                                              1. Conn PJ, Rodriguez AL, Ayala JE, Jones CK, Barrett R, Niswender CM<\/strong>, Weaver CD, Jadhav S, Sheffler DJ, Hammond AS, Williams R, Sharma S, Lindsley CW. Allosteric modulators of metabotropic glutamate receptor 5 as a novel approach for the treatment of CNS disorders. 6th<\/sup> International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy, 2008.<\/li>\n<\/ol>\n

                                                                                                 <\/p>\n

                                                                                                  \n
                                                                                                1. Jones CK, Xiang Z, Jones PJ, Byun NE, Hackler EA, Rodriguez AL, Ayala JE, Niswender CM<\/strong>, Jadhav S, Sheffler DJ, Hammond AS, Barrett R, Thompson AD, Williams R, Gore CJ, Weaver CD, Lindsley CW, Conn PJ. Novel allosteric modulators of metabotropic glutamate receptors 2 and 5 for the treatment of schizophrenia. 6th<\/sup> International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy, 2008.<\/li>\n<\/ol>\n

                                                                                                  \u00a0<\/strong><\/p>\n

                                                                                                    \n
                                                                                                  1. Niswender CM<\/strong>, Johnson KA, Weaver CD, Jones CK, Luo Q, Rodriguez AL, Marlo JE, de Paulis T, Thompson AD, Days E, Nalywajko T, Austin C, Williams M, Ayala JE, Williams R, Lindsley CW, Conn PJ. Allosteric modulation of mGluR4: a novel therapeutic direction for the treatment of Parkinson\u2019s disease. 6th<\/sup> International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy, 2008.<\/li>\n<\/ol>\n

                                                                                                    \u00a0<\/strong><\/p>\n

                                                                                                      \n
                                                                                                    1. Niswender CM<\/strong>, Johnson KA, Luo Q, Williams R, Ayala JE, Saleh S, Orton D, Weaver CD, Conn PJ. Permissive antagonism induced by negative allosteric modulators of mGluR7. 6th<\/sup> International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy, 2008.<\/li>\n<\/ol>\n

                                                                                                      \u00a0<\/strong><\/p>\n

                                                                                                        \n
                                                                                                      1. Niswender CM<\/strong>, Hopkins CR, Jones CK, Thompson AD, Engers S, Williams R, Zhou S, Salovich JM, Cheung YY, Gogliotti R, Gentry P, Johnson KA, Jadhav S, Menon U, Zamorano R, Days EL, Lindsley CW, Weaver CD, Conn PJ. Recent progress in the development of positive allosteric modulators of mGluR4 for the treatment of Parkinson\u2019s disease. Society for Neuroscience Abstracts, 2009.<\/li>\n<\/ol>\n

                                                                                                         <\/p>\n

                                                                                                          \n
                                                                                                        1. Sheffler CJ, Williams R, Bridges TM, Xiang Z, Kane AS, Byun NE, Mock MM, Zheng F, Lewis LM, Jones CK, Niswender CM<\/strong>, Weaver CD, Lindsley CW, Conn PJ. A novel selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonist reduces seizures without impairing hippocampal dependent learning. Society for Neuroscience Abstracts, 2009.<\/li>\n<\/ol>\n

                                                                                                          \u00a0<\/strong><\/p>\n

                                                                                                            \n
                                                                                                          1. Niswender CM<\/strong>, Hopkins CR, Jones CK, Thompson AD, Engers S, Williams R, Zhou S, Salovich JM, Cheung YY, Gogliotti R, Gentry P, Johnson KA, Jadhav S, Menon U, Zamorano R, Days EL, Lindsley CW, Weaver CD, Conn PJ. The development of positive allosteric modulators of mGluR4 for the treatment of Parkinson\u2019s disease. International Parkinson\u2019s Disease Congress, 2009.<\/li>\n<\/ol>\n

                                                                                                             <\/p>\n

                                                                                                              \n
                                                                                                            1. Engers DW, Le U, Zhou Y, Jones CK, Thompson AD, Jadhav S, Menon UN, Zamorano R, Daniels JS, Morrison R, Blobaum AL, Weaver CD, Conn PJ, Lindsley CW, Niswender CM<\/strong>, Hopkins CR. Discovery and SAR development of a series of N<\/em>-(4-acetamido)- and 4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides as Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4:\u00a0 A Novel Approach for the Treatment of Parkinson\u2019s DiseaseHigh Throughput Chemistry and Chemical Biology Gordon Conference, Les Diablerets, Switzerland, June 2010.<\/li>\n<\/ol>\n

                                                                                                               <\/p>\n

                                                                                                                \n
                                                                                                              1. Gogliotti RD. Hopkins CR, Jones CK, Thompson AS, Engers D, Salovich JM, Cheung Y-Y, Williams R, Gentry PR, Zhou Y, Johnson K, Jadhav S, Menon UN, Zamorano R, Lindslye CW, Conn PJ, Niswender CM<\/strong>. Discovery and SAR development of positive allosteric modulators of metabotropic glutamate receptor 4: a novel approach for the treatment of Parkinson\u2019s Disease. French American Chemical Society, Obernai France, June 2010.<\/li>\n<\/ol>\n

                                                                                                                 <\/p>\n

                                                                                                                  \n
                                                                                                                1. Utley TJ, Lebois EP, Bridges TM, Melancon BJ, Wood MR, Niswender CM<\/strong>, Lindsley CW, Conn PJ. Identification and characterization of a novel M1 selective muscarinic actylcholine receptor antagonist from an M1 agonist scaffold. Society for Neuroscience Abstracts, 2010.<\/li>\n<\/ol>\n

                                                                                                                   <\/p>\n

                                                                                                                    \n
                                                                                                                  1. Johnson KA, Sheffler CJ, Niswender CM<\/strong>, Xiang Z, Conn PJ. Group II metabotropic glutamate receptor activation induces long-term depression of excitatory transmission in the substantia nigra pars reticulata. Society for Neuroscience Abstracts, 2010.<\/li>\n<\/ol>\n

                                                                                                                     <\/p>\n

                                                                                                                      \n
                                                                                                                    1. Yin S, Zamorano R, Conn PJ, Niswender CM<\/strong>. Histamine: an endogenous allosteric modulator of metabotropic glutamate receptors. Society for Neuroscience Abstracts, 2010.<\/li>\n<\/ol>\n

                                                                                                                      \u00a0<\/strong><\/p>\n

                                                                                                                        \n
                                                                                                                      1. Niswender CM<\/strong>, Hopkins CR, Jones CK, Engers D, Thompson AD, Gogliotti RD, Blobaum AE, Jadhav S, Salovich JM, Cheung Y-Y, Morrison RD, Mulder ML, Bolinger J, Dawson ES, Zamorano R, Vinson PN, Bubser M, Brewer KA, Daniels JS, Lindsley CW, Conn PJ. mGluR4 positive allosteric modulator development for the treatment of CNS disorders. Society for Neuroscience Abstracts, 2010.<\/li>\n<\/ol>\n

                                                                                                                         <\/p>\n

                                                                                                                          \n
                                                                                                                        1. Thompson AD, Jones CK, Bubser M, Niswender CM<\/strong>, Hopkins CR, Engers D, Jadhav S, Lindsley CW, Conn PJ. VU0364770, a potent and systemically active positive allosteric modulator of mGluR4, produces robust efficacy in preclinical rodent models of Parkinson\u2019s Disease. Society for Neuroscience Abstracts, 2010.<\/li>\n<\/ol>\n

                                                                                                                           <\/p>\n

                                                                                                                            \n
                                                                                                                          1. Herman EJ, Gregory KJ, Jones CK, Hammond AS, Stauffer SR, Manka J, Weaver C, Niswender CM<\/strong>, Steckler T, Lavreysen H, MacDonald G, Bartolome JM, Mackie C, Lindsley CW, Conn PJ. Optimization of n-aryl piperzaines as selectivity mGluR5 potentiators with efficacy in a rodent model predictive of anti-psychotic activity. Society for Neuroscience Abstracts, 2010.<\/li>\n<\/ol>\n

                                                                                                                             <\/p>\n

                                                                                                                              \n
                                                                                                                            1. Vinson PN, Hammond AS, Rodriguez AL, Townsend SD, Niswender CM<\/strong>, Lindsley CW, Conn PJ. Novel allosteric ligands of mGluR5 conduct unique actions by binding to a distinct site. Society for Neuroscience Abstracts, 2010.<\/li>\n<\/ol>\n

                                                                                                                               <\/p>\n

                                                                                                                                \n
                                                                                                                              1. Noetzel M, Cho HP, Days E, Zhou Y, Rodriguez AL, Steckler T, Lavreysen H, Stauffer SR, Niswender CM<\/strong>, Lindsley CW, Weaver CS, Conn PJ. Receptor expression level influences the effect of allosteric modulators at metabotropic glutamate receptor 5. Society for Neuroscience Abstracts, 2010.<\/li>\n<\/ol>\n

                                                                                                                                \u00a0<\/strong><\/p>\n

                                                                                                                                  \n
                                                                                                                                1. Niswender CM<\/strong>, Jones CK, Hopkins CR, Thompson AD, Bubser M, Engers DW, Gogliotti RD, Blobaum AL, Salovich JM, Cheung YY, Morrison RD, Dawson ES, Zamorano R, Brewer KA, Daniels JS, Lindsley CW, Conn PJ. mGlu4 receptor positive allosteric modulator development for the treatment of CNS disorders. 7th<\/sup> International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy, 2011.<\/li>\n<\/ol>\n

                                                                                                                                   <\/p>\n

                                                                                                                                    \n
                                                                                                                                  1. Blobaum AL, Morrison RD, Jadhav S, Engers DW, Lindsley SR, Zhou Y, Gogliotti RD, Jones CK, Niswender CM<\/strong>, Conn PJ, Lindsley CW, Hopkins CR, Daniels JS. Drug metabolism and disposition of a novel N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamide series of positive allosteric modulators of metabotropic glutamate receptor 4:identification of ML182 as an orally efficacious mGuR4-PAM. 7th<\/sup> International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy, 2011.<\/li>\n<\/ol>\n

                                                                                                                                     <\/p>\n

                                                                                                                                      \n
                                                                                                                                    1. Conn PJ, Stauffer SR, Zhou S, Manka J, Williams R, Noetzel MJ, Gregory KJ, Vinson P, Niswender CM<\/strong>, Jones CK, Steckler T, MacDonald G, Lindsley CW. Allosteric modulators of metabotropic glutamate receptor 5 for treatment of schizophrenia. 7th<\/sup> International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy, 2011.<\/li>\n<\/ol>\n

                                                                                                                                       <\/p>\n

                                                                                                                                        \n
                                                                                                                                      1. Dawson ES, Smith JA, Niswender CM,<\/strong> Hopkins CR, Gogliotti RD, Stauffer SR, Lindsley CW, Conn PJ. Shape-based virtual screens to identify movel group I and III mGlu receptor allosteric modulator chemotypes. 7th<\/sup> International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy, 2011.<\/li>\n<\/ol>\n

                                                                                                                                         <\/p>\n

                                                                                                                                          \n
                                                                                                                                        1. Engers DW, Le UM, Zhou Y, Thompson AD, Jadhav S, Gogliotti RD, Lindlsey SR, Bolinger JL, Menon UN, Zamorano R, Daniels JS, Morrison RD, Blobaum AL, Jones CK, Weaver CD, Conn PJ, Lindsley CW, Niswender CM<\/strong>, Hopkins CR. Discovery and SAR development of a novel series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides, including ML182, as positive allosteric modulators of metabotropic glutamate receptor 4: a novel approach for the treatment of Parksinon\u2019s disease.\u00a0 7th<\/sup> International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy, 2011.<\/li>\n<\/ol>\n

                                                                                                                                           <\/p>\n

                                                                                                                                            \n
                                                                                                                                          1. Gregory KJ, Dong EN, Reiff SD, Rook JM, Noetzel MJ, Cho HP, Kaufmann KW, Manka JT, Zhou YS, Vinson PN, Stauffer SR, Niswender CM,<\/strong> Lindsley CW, Meiler J, Conn PJ. Application of an operational model of allosterism to investigate the structural determinants of positive allosteric modulator of metabotropic glutamate receptor 5. 7th<\/sup> International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy, 2011.<\/li>\n<\/ol>\n

                                                                                                                                             <\/p>\n

                                                                                                                                              \n
                                                                                                                                            1. Johnson KA, Niswender CM<\/strong>, Conn PJ, Ziang Z. Activation of group II metabotropic glutamate receptors induces long term depression of excitatory synaptic transmissionin the substantia nigra pars reticulate. 7th<\/sup> International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy, 2011.<\/li>\n<\/ol>\n

                                                                                                                                               <\/p>\n

                                                                                                                                                \n
                                                                                                                                              1. Jones CK, Rodriguez AL, Rook JM, Niswender CM<\/strong>, Emmitte KA, Felts AS, Lawson KP, Bates BS, Blobaum AL, Morrison RD, Byers FW, Daniels JS, Carpenter RL, Healy A, Shumway M, Lindsley CW, Conn PJ. Novel mGluR5 NAMs: potential utility to treatment in Fraile X Syndrome and affective disorders. 7th<\/sup> International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy, 2011.<\/li>\n<\/ol>\n

                                                                                                                                                 <\/p>\n

                                                                                                                                                  \n
                                                                                                                                                1. Noetzel MJ, Gregory KJ, Rook JM, Vinson PN, Cho HP, Stauffer SR, Xiang Z, Daniels JS, Niswender CM<\/strong>, Lindsley CW, Conn PJ. Characterization of novel metabotropic glutamate receptor 5 positive allosteric modulators utilizing in vitro and in vivo studies. 7th<\/sup> International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy, 2011.<\/li>\n<\/ol>\n

                                                                                                                                                   <\/p>\n

                                                                                                                                                    \n
                                                                                                                                                  1. Stauffer SR, S Zhou, Manka J, Rodriguez A, Noetzel MJ, Gregory KJ, Vinson PN, Niswender CM<\/strong>, Dawson E, Jones CK, Lambert R, Thompson AG, Daniels JS, Bridges T, Lavreysen H, Bartolome JM, Mackie C, Steckler T, MacDonald G, Lindsley CW, Conn PJ. Identification and optimization of mGlu5 PAMs which activate the receptor at allosteric sites outside the MPEP site. 7th<\/sup> International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy, 2011.<\/li>\n<\/ol>\n

                                                                                                                                                     <\/p>\n

                                                                                                                                                      \n
                                                                                                                                                    1. Steckler T, Jones CK, Stauffer SR, Bartolome JM, Niswender CM<\/strong>, Lavreysen H, MacDonald G, Mackie C, Vinson P, Daniels JS, Lindsley CW, Conn PJ. mGluR5 positive allosteric modulators: an industrial perspective. 7th<\/sup> International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy, 2011.<\/li>\n<\/ol>\n

                                                                                                                                                       <\/p>\n

                                                                                                                                                        \n
                                                                                                                                                      1. Vinson PN, Rook JM, Stauffer SR, Manka J, Zhou S, Gogi K, Niswender CM<\/strong>, Jones CK, Daniels JS, Bridges T, Lavreysen H, Bartolome JM, Mackie C, Steckler T, MacDonald G, Lindsley CW, Conn PJ. Optimization of mGlu5 positive allosteric modulators for in vivo studies. 7th<\/sup> International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy, 2011.<\/li>\n<\/ol>\n

                                                                                                                                                         <\/p>\n

                                                                                                                                                          \n
                                                                                                                                                        1. Yin S, Zamorano R, Conn PJ, Niswender CM<\/strong>. Histamine: an endogenous modulator of metabotropic glutamate receptors. 7th<\/sup> International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy, 2011.<\/li>\n
                                                                                                                                                        2. Dickerson JW, Thompson AD, Jones CK, Niswender CM<\/strong>, Hopkins CR, Lindsley CW, Conn PJ. Co-administration of an mGlu4 positive allosteric modulator and the A2A antagonist preladenant improved efficacy in preclinical models of Parkinson\u2019s disease. Society for Neuroscience abstracts, 2011.<\/li>\n<\/ol>\n

                                                                                                                                                           <\/p>\n

                                                                                                                                                            \n
                                                                                                                                                          1. Digby GJ, Utley TJ, Walker AG, Sheffler CJ, Xiang Z, Plumley H, Davis AA, Byun NE, Niswender CM<\/strong>, Jones CK, Lindsley CW, Conn PJ. Characterization of M1-selective partial agonists VU0364572 and VU0357017: evidence for brain-region specific electrophysiological and behavioral effects. Society for Neuroscience abstracts, 2011.<\/li>\n<\/ol>\n

                                                                                                                                                             <\/p>\n

                                                                                                                                                              \n
                                                                                                                                                            1. Klein MT, Digby GJ, Pancani T, Niswender C<\/strong>, Tarr C, Poslusney M, Melancon BJ, Wood MR, Lindsley CW, Conn PJ. Biasing acetylcholine signaling at human M4 muscarinic receptors: Effects of novel positive allosteric modulators. Society for Neuroscience abstracts, 2012.<\/li>\n<\/ol>\n

                                                                                                                                                               <\/p>\n

                                                                                                                                                                \n
                                                                                                                                                              1. Rook JM, Noetzel MJ, Pouliot WA, Bridges TM, Vinson PN, Zhou Y, Gogliotti RD, Manka JT, Stauffer SR, Niswender CM<\/strong>, Dudek FE, Daniels JS, Jones CK, Lindsely CW, Conn PJ. Molecular actions of positive allosteric agonists of mGlu5 determine efficacy versus adverse effect liability in animal models. Society for Neuroscience abstracts, 2012.<\/li>\n<\/ol>\n

                                                                                                                                                                 <\/p>\n

                                                                                                                                                                  \n
                                                                                                                                                                1. Dickerson JW, Nedelcovych MT, Stauffer SR, Hopkins CR, Niswender CM<\/strong>, Lindsley CW, Jones CK, Conn PJ. Effects of metabotropic glutamate receptor activation on cytokine release and cognition during neuroinflammation. Society for Neuroscience abstracts, 2012.<\/li>\n<\/ol>\n

                                                                                                                                                                   <\/p>\n

                                                                                                                                                                    \n
                                                                                                                                                                  1. Goshal A, Pouget P, Byun N, Stauffer SR, Rook JM, Rodriguez AL, Niswender CM<\/strong>, Jones CK, Lindsley CW, Conn PJ. Effects of metabotropic glutamate receptor 5 activation on neurophysiological sensory processing in vivo<\/em>: Implications in Schizophrenia. Society for Neuroscience abstracts, 2012.<\/li>\n<\/ol>\n

                                                                                                                                                                     <\/p>\n

                                                                                                                                                                      \n
                                                                                                                                                                    1. Noetzel M, Gregory KJ, Vinson PN, Manka JT, Stauffer SR, Xiang Z, Daniels JS, Niswender CM<\/strong>, Lindsley CW, Conn PJ. Characterization of a potent and efficacious metabotropic glutamate receptor 5 positive allosteric modulator from the CPPHA series. Society for Neuroscience abstracts, 2012.<\/li>\n<\/ol>\n

                                                                                                                                                                       <\/p>\n

                                                                                                                                                                        \n
                                                                                                                                                                      1. Gogliotti RG, Klar R, Zamorano M, Rook JM, Conn PJ, Niswender CM<\/strong>. mGlu5 positive allosteric modulation as a therapeutic strategy for Rett syndrome: weighing the risks and the rewards. Cold Spring Harbor Conference \u201cWiring the Brain\u201d, 2013.<\/li>\n<\/ol>\n

                                                                                                                                                                         <\/p>\n

                                                                                                                                                                          \n
                                                                                                                                                                        1. Kaufman, Romaine L, Days E, Pascual C, Yang L, Zou B, Malik A, Du Y, Sliwoski G, Morrison R, Denton J, Niswender C<\/strong>, Daniels S, Sulikowski G, Xie XS, Lindsley C, Weaver C. Discovery and characterization of ML297, a novel, in vivo active small molecule activator of G-protein-coupled in ward rectifying potassium (GIRK) channels. Society for Neuroscience abstracts, 2013.<\/li>\n<\/ol>\n

                                                                                                                                                                           <\/p>\n

                                                                                                                                                                            \n
                                                                                                                                                                          1. Gentry PR, Kokubo M, Foster DJ, Bridges TM, Niswender CM<\/strong>, Daniels JS, Conn PJ, Wood MR, Lindsley CW. Discovery, synthesis, and pharmacological characterization of novel, highly selective M5<\/sub> allosteric modulators. Society for Neuroscience abstracts, 2013.<\/li>\n<\/ol>\n

                                                                                                                                                                             <\/p>\n

                                                                                                                                                                              \n
                                                                                                                                                                            1. Ghoshal A, Rook JM, Johnson KA, Lv X, Dickerson JW, Lambert Collier RL, Vinson PN, Stauffer SR, Jones CK, Niswender CM<\/strong>, Lindsley CW, Xiang Z, Conn PJ. Stimulus bias of metabotropic glutamate receptor 5 allosteric modulators-impact on CNS effects and implications for therapeutic use. Society for Neuroscience abstracts, 2013.<\/li>\n<\/ol>\n

                                                                                                                                                                               <\/p>\n

                                                                                                                                                                                \n
                                                                                                                                                                              1. Noetzel M, Yin S, Zamorano R, Johnson KA, Conn PJ, Niswender CM<\/strong>. Receptor dimerization changed the ability of mGlu4 positive allosteric modulators to potentiate L-AP4-induced responses. Society for Neuroscience abstracts, 2013.<\/li>\n<\/ol>\n

                                                                                                                                                                                 <\/p>\n

                                                                                                                                                                                  \n
                                                                                                                                                                                1. Rook JM, Walker AG, Huan Q, Stauffer SR, Niswender CM<\/strong>, Daniels JS, Jones CK, Lindsley CW, Conn PJ. Allosteric modulators of muscarinic acetylcholine and metabotropic glutamate receptors as promising therapeutic strategies for cognition enhancement in Alzheimer\u2019s disease. Society for Neuroscience abstracts, 2013.<\/li>\n<\/ol>\n

                                                                                                                                                                                   <\/p>\n

                                                                                                                                                                                    \n
                                                                                                                                                                                  1. Klar R, Gogliotti RG, Zamorano R, Walker AG, Xiang Z, Conn PJ, Niswender CM<\/strong>. Activation of metabotropic glutamate receptor 7 (mGlu7) rescues hippocampal synaptic plasticity in a mouse model of Rett syndrome. International Rett Syndrome Foundation Symposium, 2014.<\/li>\n<\/ol>\n

                                                                                                                                                                                     <\/p>\n

                                                                                                                                                                                      \n
                                                                                                                                                                                    1. Gogliotti RG, Klar R, Ghoshal A, Zamorano R, Rook J, Conn PJ, Niswender CM<\/strong>. The development of mGlu5 positive allosteric modulators as Rett Syndrome therapeutics. International Rett Syndrome Foundation Symposium, 2014.<\/li>\n<\/ol>\n

                                                                                                                                                                                       <\/p>\n

                                                                                                                                                                                        \n
                                                                                                                                                                                      1. Gogliotti R, Klar R, Zamorano R, Rook J, Walker A, Xiang Z, Conn PJ, Niswender CM<\/strong>. Metabotropic glutamate receptor potentiation as a therapeutic direction in Rett syndrome. International Rett Syndrome Foundation Symposium, 2014.<\/li>\n<\/ol>\n

                                                                                                                                                                                         <\/p>\n

                                                                                                                                                                                          \n
                                                                                                                                                                                        1. Gogliotti RG, Klar R, Ghoshal A, Zamorano R, Rook J, Conn PJ, Niswender CM<\/strong>. The development of mGlu5 positive allosteric modulators as Rett Syndrome therapeutics. 8th<\/sup> International Congress on Metabotropic Glutamate Receptors, 2014.<\/li>\n<\/ol>\n

                                                                                                                                                                                           <\/p>\n

                                                                                                                                                                                            \n
                                                                                                                                                                                          1. Klar R, Gogliotti RG, Zamorano R, Walker AG, Xiang Z, Conn PJ, Niswender CM<\/strong>. Metabotropic glutamate receptor 7: a novel target for the treatment of Rett syndrome. 8th<\/sup> International Congress on Metabotropic Glutamate Receptors, 2014.<\/li>\n<\/ol>\n

                                                                                                                                                                                             <\/p>\n

                                                                                                                                                                                              \n
                                                                                                                                                                                            1. Klar R, Gogliotti RG, Zamorano R, Walker AG, Xiang Z, Conn PJ, Niswender CM. <\/strong>Activation of mGlu7<\/sub> is Critical for Hippocampal Plasticity and is a Potential Therapeutic Target for the Treatment of Rett Syndrome. 8th<\/sup> International Congress on Metabotropic Glutamate Receptors, 2014.<\/li>\n<\/ol>\n

                                                                                                                                                                                               <\/p>\n

                                                                                                                                                                                                \n
                                                                                                                                                                                              1. Ghoshal A, Rook JM, Dickerson JW, Morrison RD, Stauffer SR, Jones CK, Daniels JS, Niswender CM<\/strong>, Lindsley CW, Conn PJ. Evaluation of the therapeutic efficacy of M1<\/sub> muscarinic acetylcholine receptor potentiation in chronic phencyclidine treated mouse model of schizophrenia. Society for Neuroscience abstracts, 2014.<\/li>\n<\/ol>\n

                                                                                                                                                                                                 <\/p>\n

                                                                                                                                                                                                  \n
                                                                                                                                                                                                1. Noetzel MJ, Rook JM, Lamsal A, Morrison RD, Cho HP, Niswender CM<\/strong>, Daniels JS, Stauffer SR, Lindsley CW, Conn PJ. M1 muscarinic receptor expression levels influence the effect of positive allosteric modulators. Society for Neuroscience abstracts, 2014.<\/li>\n<\/ol>\n

                                                                                                                                                                                                   <\/p>\n

                                                                                                                                                                                                    \n
                                                                                                                                                                                                  1. Fisher NM, Gogliotti RG, Klar R, Zamorano R, Stansley BJ, Walker AG, Blobaum AL, Engers D, Hopkins CR, Daniels JS, Lindsley CW, Xiang Z, Conn PJ, and Niswender C.M<\/strong>. Therapeutic potential of mGlu7<\/sub> in the treatment of MeCP2-Related Disorders. Vanderbilt Kennedy Center Science Day, 2015.<\/li>\n<\/ol>\n

                                                                                                                                                                                                     <\/p>\n

                                                                                                                                                                                                      \n
                                                                                                                                                                                                    1. Stansley BJ, Gogliotti RG, Klar R, Fisher NM, Emmitte, KA, Lindsley C, Conn PJ, Niswender CM<\/strong>. Therapeutic potential of mGlu3 <\/sub>antagonism in correcting synaptic plasticity defects in a mouse model of MECP2 Duplication Syndrome. Vanderbilt Kennedy Center Science Day, 2015.<\/li>\n<\/ol>\n

                                                                                                                                                                                                       <\/p>\n

                                                                                                                                                                                                        \n
                                                                                                                                                                                                      1. Klar R, Gogliotti RG, Zamorano R, Walker AG, Xiang Z, Conn PJ, Niswender CM. <\/strong>Activation of mGlu7<\/sub> is Critical for Hippocampal Plasticity and is a Potential Therapeutic Target for the Treatment of Rett Syndrome. Society for Neuroscience, 2015.<\/li>\n<\/ol>\n

                                                                                                                                                                                                         <\/p>\n

                                                                                                                                                                                                          \n
                                                                                                                                                                                                        1. Gogliotti RG, Klar R, Ghoshal A, Zamorano R, Rook JM, Stauffer SR, Malosh C, Vinson PN, Jones CK, Lindsley CW, Conn PJ, Niswender CM. <\/strong>A novel mGlu5<\/sub> positive allosteric modulator improves phenotype and rescues synaptic plasticity defects in a mouse model of Rett syndrome. Society for Neuroscience, 2015.<\/li>\n<\/ol>\n

                                                                                                                                                                                                           <\/p>\n

                                                                                                                                                                                                            \n
                                                                                                                                                                                                          1. Gogliotti RG, Senter RK, Ghoshal A, Zamorano R, Rook JM, Stauffer SR, Malosh C, Vinson P, Jones CK, Lindsley CW, Conn PJ, Niswender, CM<\/strong>. mGlu5<\/sub> positive allosteric modulators as a therapeutic strategy for Rett syndrome. Vanderbilt Kennedy Center Science Day, Nashville, TN September 2015.<\/li>\n<\/ol>\n

                                                                                                                                                                                                             <\/p>\n

                                                                                                                                                                                                              \n
                                                                                                                                                                                                            1. Stansley BJ, Gogliotti RG, Klar R, Fisher N, Emmitte K, Lindsley C, Conn PJ, and Niswender<\/strong> CM<\/strong>. mGlu3<\/sub> negative allosteric modulation corrects hippocampal synaptic plasticity impairments in a model of MECP2<\/em> Duplication syndrome. Vanderbilt Kennedy Center Science Day, Nashville, TN, September 2015.<\/li>\n<\/ol>\n

                                                                                                                                                                                                               <\/p>\n

                                                                                                                                                                                                                \n
                                                                                                                                                                                                              1. Stansley BJ, Gogliotti RG, Klar R, Fisher N, Loch M, Emmitte K, Lindsley C, Conn PJ, and Niswender CM<\/strong>. Therapeutic potential of mGlu3<\/sub> antagonism in correcting synaptic plasticity defects in a mouse model of MECP2<\/em> Duplication Syndrome. Neuropharmacology Conference, November 2015.<\/li>\n<\/ol>\n

                                                                                                                                                                                                                 <\/p>\n

                                                                                                                                                                                                                  \n
                                                                                                                                                                                                                1. Fisher NM, Gogliotti RG, Klar R, Zamorano R, Stansley BJ, Walker AG, Blobaum AL, Engers D, Hopkins CR, Daniels JS, Lindsley CW, Xiang Z, Jones CK, Conn PJ, Niswender CM<\/strong>. Therapeutic potential of mGlu7<\/sub> in the treatment of MECP2<\/em>-related disorders. Neuropharmacology Conference, November 2015.<\/li>\n<\/ol>\n

                                                                                                                                                                                                                   <\/p>\n

                                                                                                                                                                                                                    \n
                                                                                                                                                                                                                  1. Stansley BJ, Gogliotti RG, Fisher N, Loch M, Emmitte K, Lindsley C, Conn PJ, and Niswender<\/strong> CM<\/strong>. The therapeutic potential of mGlu3<\/sub> antagonism in correcting synaptic plasticity defects in a mouse model of MECP2<\/em> Duplication syndrome. Experimental Biology\/American Society for Pharmacology and Experimental Therapeutics, April 2016.<\/li>\n<\/ol>\n

                                                                                                                                                                                                                     <\/p>\n

                                                                                                                                                                                                                      \n
                                                                                                                                                                                                                    1. Stansley BJ, Gogliotti RG, Fisher N, Loch M, Emmitte K, Lindsley C, Conn PJ, and Niswender CM<\/strong>. The therapeutic potential of mGlu3<\/sub> modulation in MECP2<\/em>-related disorders. Rett Syndrome Symposium, June 2016.<\/li>\n<\/ol>\n

                                                                                                                                                                                                                       <\/p>\n

                                                                                                                                                                                                                        \n
                                                                                                                                                                                                                      1. Fisher NM, Gogliotti RG, Senter R, Stansley BJ, Gould RG, Walker AG, Zamorano R, Adams JJ, Blobaum AL, Engers S, Hopkins CR, Lindsley CW, Xiang Z, Jones CK, Conn PJ, Niswender CM<\/strong>. Metabotropic glutamate receptor 7 as a therapeutic target for MECP2<\/em>-related disorders. Rett Syndrome Symposium, June 2016.<\/li>\n<\/ol>\n

                                                                                                                                                                                                                         <\/p>\n

                                                                                                                                                                                                                          \n
                                                                                                                                                                                                                        1. Gogliotti RG, Senter RK, Ghoshal A, Zamorano R, Rook JM, Stauffer SR, Malosh C, Vinson P, Jones CK, Lindsley CW, Conn PJ, Niswender, CM<\/strong>. mGlu5<\/sub> positive allosteric modulators as a therapeutic strategy for Rett syndrome. Rett Syndrome Symposium, June 2016<\/li>\n<\/ol>\n

                                                                                                                                                                                                                           <\/p>\n

                                                                                                                                                                                                                            \n
                                                                                                                                                                                                                          1. Niswender CM, Gogliotti RG, Fisher NM, Senter RK, Gould RW, Adams JJ, Stansley BJ, Walker AG, Zamorano R, Blobaum AL, Engers DW, Hopkins CR, Lindsley CW, Conn PJ. Society for Neuroscience, November 2016.<\/li>\n<\/ol>\n

                                                                                                                                                                                                                             <\/p>\n

                                                                                                                                                                                                                              \n
                                                                                                                                                                                                                            1. Moehle MS, Pancani T, Byun NE, Xiang Zm, Wess J, Rook MR, Niswender CM, Jones CK, Lindsley CW, Conn PJ. Activation in the SNr evokes GABA release and increased motor activity and is tonically inhibited by M4<\/sub>signaling. Society for Neuroscience, November 2016.<\/li>\n<\/ol>\n

                                                                                                                                                                                                                               <\/p>\n

                                                                                                                                                                                                                               <\/p>\n

                                                                                                                                                                                                                              ***Best poster winner at respective conference<\/p>\n

                                                                                                                                                                                                                              \u00a0<\/u><\/strong><\/p>\n


                                                                                                                                                                                                                              \n<\/u><\/strong><\/p>\n

                                                                                                                                                                                                                              JOURNAL ARTICLES <\/u><\/strong>(1-183<\/a>)<\/u><\/strong><\/p>\n

                                                                                                                                                                                                                               <\/p>\n

                                                                                                                                                                                                                               <\/p>\n

                                                                                                                                                                                                                                \n
                                                                                                                                                                                                                              1. Aldrich, L. N., Lebois, E. P., Lewis, L. M., Nalywajko, N. T., Niswender, C. M., Weaver, C. D., Conn, P. J., and Lindsley, C. W. (2009) MAOS ls for the general synthesis and lead optimization of 3,6-disubstituted-[1,2,4]triazolo[4,3-b]pyridazines. Tetrahedron Lett<\/em> 50<\/strong>, 212-215<\/li>\n
                                                                                                                                                                                                                              2. Alizadeh, A., Fitch, K. R., Niswender, C. M., McKnight, G. S., and Barsh, G. S. (2008) Melanocyte-lineage expression of Cre recombinase using Mitf regulatory elements. Pigment Cell Melanoma Res<\/em> 21<\/strong>, 63-69<\/li>\n
                                                                                                                                                                                                                              3. Amato, R. J., Felts, A. S., Rodriguez, A. L., Venable, D. F., Morrison, R. D., Byers, F. W., Daniels, J. S., Niswender, C. M., Conn, P. J., Lindsley, C. W., Jones, C. K., and Emmitte, K. A. (2013) Substituted 1-Phenyl-3-(pyridin-2-yl)urea negative allosteric modulators of mGlu5: discovery of a new tool compound VU0463841 with activity in rat models of cocaine addiction. ACS Chem Neurosci<\/em> 4<\/strong>, 1217-1228<\/li>\n
                                                                                                                                                                                                                              4. Ayala, J. E., Niswender, C. M., Luo, Q., Banko, J. L., and Conn, P. J. (2008) Group III mGluR regulation of synaptic transmission at the SC-CA1 synapse is developmentally regulated. Neuropharmacology<\/em> 54<\/strong>, 804-814<\/li>\n
                                                                                                                                                                                                                              5. Backstrom, J. R., Chang, M. S., Chu, H., Niswender, C. M., and Sanders-Bush, E. (1999) Agonist-directed signaling of serotonin 5-HT2C receptors: differences between serotonin and lysergic acid diethylamide (LSD). Neuropsychopharmacology<\/em> 21<\/strong>, 77S-81S<\/li>\n
                                                                                                                                                                                                                              6. Bartolome-Nebreda, J. M., Conde-Ceide, S., Delgado, F., Iturrino, L., Pastor, J., Pena, M. A., Trabanco, A. A., Tresadern, G., Wassvik, C. M., Stauffer, S. R., Jadhav, S., Gogi, K., Vinson, P. N., Noetzel, M. J., Days, E., Weaver, C. D., Lindsley, C. W., Niswender, C. M., Jones, C. K., Conn, P. J., Rombouts, F., Lavreysen, H., Macdonald, G. J., Mackie, C., and Steckler, T. (2013) Dihydrothiazolopyridone derivatives as a novel family of positive allosteric modulators of the metabotropic glutamate 5 (mGlu5) receptor. J Med Chem<\/em> 56<\/strong>, 7243-7259<\/li>\n
                                                                                                                                                                                                                              7. Bates, B. S., Rodriguez, A. L., Felts, A. S., Morrison, R. D., Venable, D. F., Blobaum, A. L., Byers, F. W., Lawson, K. P., Daniels, J. S., Niswender, C. M., Jones, C. K., Conn, P. J., Lindsley, C. W., and Emmitte, K. A. (2014) Discovery of VU0431316: a negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. Bioorg Med Chem Lett<\/em> 24<\/strong>, 3307-3314<\/li>\n
                                                                                                                                                                                                                              8. Bender, A. M., Weiner, R. L., Luscombe, V. B., Ajmera, S., Cho, H. P., Chang, S., Zhan, X., Rodriguez, A. L., Niswender, C. M., Engers, D. W., Bridges, T. M., Conn, P. J., and Lindsley, C. W. (2017) Discovery and optimization of 3-(4-aryl\/heteroarylsulfonyl)piperazin-1-yl)-6-(piperidin-1-yl)pyridazines as novel, CNS penetrant pan-muscarinic antagonists. Bioorg Med Chem Lett<\/em> 27<\/strong>, 3576-3581<\/li>\n
                                                                                                                                                                                                                              9. Bender, A. M., Weiner, R. L., Luscombe, V. B., Cho, H. P., Niswender, C. M., Engers, D. W., Bridges, T. M., Conn, P. J., and Lindsley, C. W. (2017) Synthesis and evaluation of 4,6-disubstituted pyrimidines as CNS penetrant pan-muscarinic antagonists with a novel chemotype. Bioorg Med Chem Lett<\/em> 27<\/strong>, 2479-2483<\/li>\n
                                                                                                                                                                                                                              10. Berg, K. A., Cropper, J. D., Niswender, C. M., Sanders-Bush, E., Emeson, R. B., and Clarke, W. P. (2001) RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity. Br J Pharmacol<\/em> 134<\/strong>, 386-392<\/li>\n
                                                                                                                                                                                                                              11. Blobaum, A. L., Bridges, T. M., Byers, F. W., Turlington, M. L., Mattmann, M. E., Morrison, R. D., Mackie, C., Lavreysen, H., Bartolome, J. M., Macdonald, G. J., Steckler, T., Jones, C. K., Niswender, C. M., Conn, P. J., Lindsley, C. W., Stauffer, S. R., and Daniels, J. S. (2013) Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug-drug interactions. Drug Metab Dispos<\/em> 41<\/strong>, 2066-2075<\/li>\n
                                                                                                                                                                                                                              12. Bridges, T. M., Marlo, J. E., Niswender, C. M., Jones, C. K., Jadhav, S. B., Gentry, P. R., Plumley, H. C., Weaver, C. D., Conn, P. J., and Lindsley, C. W. (2009) Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins. J Med Chem<\/em> 52<\/strong>, 3445-3448<\/li>\n
                                                                                                                                                                                                                              13. Bridges, T. M., Niswender, C. M., Jones, C. K., Lewis, L. M., Weaver, C. D., Wood, M. R., Daniels, J. S., Conn, P. J., and Lindsley, C. W. (2010) Discovery of a Highly Selective in vitro and in vivo M4 Positive Allosteric Modulator (PAM) Series with Greatly Improved Human Receptor Activity.<\/li>\n
                                                                                                                                                                                                                              14. Bridges, T. M., Rook, J. M., Noetzel, M. J., Morrison, R. D., Zhou, Y., Gogliotti, R. D., Vinson, P. N., Xiang, Z., Jones, C. K., Niswender, C. M., Lindsley, C. W., Stauffer, S. R., Conn, P. J., and Daniels, J. S. (2013) Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanism. Drug Metab Dispos<\/em> 41<\/strong>, 1703-1714<\/li>\n
                                                                                                                                                                                                                              15. Bubser, M., Bridges, T. M., Dencker, D., Gould, R. W., Grannan, M., Noetzel, M. J., Lamsal, A., Niswender, C. M., Daniels, J. S., Poslusney, M. S., Melancon, B. J., Tarr, J. C., Byers, F. W., Wess, J., Duggan, M. E., Dunlop, J., Wood, M. W., Brandon, N. J., Wood, M. R., Lindsley, C. W., Conn, P. J., and Jones, C. K. (2014) Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents. ACS Chem Neurosci<\/em> 5<\/strong>, 920-942<\/li>\n
                                                                                                                                                                                                                              16. Burns, C. M., Chu, H., Rueter, S. M., Hutchinson, L. K., Canton, H., Sanders-Bush, E., and Emeson, R. B. (1997) Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature<\/em> 387<\/strong>, 303-308<\/li>\n
                                                                                                                                                                                                                              17. Cheung, Y. Y., Zamorano, R., Blobaum, A. L., Weaver, C. D., Conn, P. J., Lindsley, C. W., Niswender, C. M., and Hopkins, C. R. (2011) Solution-phase parallel synthesis and SAR of homopiperazinyl analogs as positive allosteric modulators of mGlu(4). ACS Comb Sci<\/em> 13<\/strong>, 159-165<\/li>\n
                                                                                                                                                                                                                              18. Cho, H. P., Engers, D. W., Venable, D. F., Niswender, C. M., Lindsley, C. W., Conn, P. J., Emmitte, K. A., and Rodriguez, A. L. (2014) A novel class of succinimide-derived negative allosteric modulators of metabotropic glutamate receptor subtype 1 provides insight into a disconnect in activity between the rat and human receptors. ACS Chem Neurosci<\/em> 5<\/strong>, 597-610<\/li>\n
                                                                                                                                                                                                                              19. Cho, H. P., Garcia-Barrantes, P. M., Brogan, J. T., Hopkins, C. R., Niswender, C. M., Rodriguez, A. L., Venable, D. F., Morrison, R. D., Bubser, M., Daniels, J. S., Jones, C. K., Conn, P. J., and Lindsley, C. W. (2014) Chemical modulation of mutant mGlu1 receptors derived from deleterious GRM1 mutations found in schizophrenics. ACS Chem Biol<\/em> 9<\/strong>, 2334-2346<\/li>\n
                                                                                                                                                                                                                              20. Conde-Ceide, S., Alcazar, J., Alonso de Diego, S. A., Lopez, S., Martin-Martin, M. L., Martinez-Viturro, C. M., Pena, M. A., Tong, H. M., Lavreysen, H., Mackie, C., Bridges, T. M., Daniels, J. S., Niswender, C. M., Jones, C. K., Macdonald, G. J., Steckler, T., Conn, P. J., Stauffer, S. R., Lindsley, C. W., and Bartolome-Nebreda, J. M. (2016) Preliminary investigation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives as a novel series of mGlu5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia. Bioorg Med Chem Lett<\/em> 26<\/strong>, 429-434<\/li>\n
                                                                                                                                                                                                                              21. Conde-Ceide, S., Martinez-Viturro, C. M., Alcazar, J., Garcia-Barrantes, P. M., Lavreysen, H., Mackie, C., Vinson, P. N., Rook, J. M., Bridges, T. M., Daniels, J. S., Megens, A., Langlois, X., Drinkenburg, W. H., Ahnaou, A., Niswender, C. M., Jones, C. K., Macdonald, G. J., Steckler, T., Conn, P. J., Stauffer, S. R., Bartolome-Nebreda, J. M., and Lindsley, C. W. (2015) Discovery of VU0409551\/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia. ACS Med Chem Lett<\/em> 6<\/strong>, 716-720<\/li>\n
                                                                                                                                                                                                                              22. Conn, P. J., Lindsley, C. W., Meiler, J., and Niswender, C. M. (2014) Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat Rev Drug Discov<\/em> 13<\/strong>, 692-708<\/li>\n
                                                                                                                                                                                                                              23. Conn, P. J., and Niswender, C. M. (2006) mGluR7’s lucky number. Proc Natl Acad Sci U S A<\/em> 103<\/strong>, 251-252<\/li>\n
                                                                                                                                                                                                                              24. Days, E., Kaufmann, K., Romaine, I., Niswender, C., Lewis, M., Utley, T., Du, Y., Sliwoski, G., Morrison, R., Dawson, E. S., Engers, J. L., Denton, J., Daniels, J. S., Sulikowski, G. A., Lindsley, C. W., and Weaver, C. D. (2010) Discovery and Characterization of a Selective Activator of the G-Protein Activated Inward-Rectifying Potassium (GIRK) Channel.<\/li>\n
                                                                                                                                                                                                                              25. Digby, G. J., Noetzel, M. J., Bubser, M., Utley, T. J., Walker, A. G., Byun, N. E., Lebois, E. P., Xiang, Z., Sheffler, D. J., Cho, H. P., Davis, A. A., Nemirovsky, N. E., Mennenga, S. E., Camp, B. W., Bimonte-Nelson, H. A., Bode, J., Italiano, K., Morrison, R., Daniels, J. S., Niswender, C. M., Olive, M. F., Lindsley, C. W., Jones, C. K., and Conn, P. J. (2012) Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models. J Neurosci<\/em> 32<\/strong>, 8532-8544<\/li>\n
                                                                                                                                                                                                                              26. Digby, G. J., Utley, T. J., Lamsal, A., Sevel, C., Sheffler, D. J., Lebois, E. P., Bridges, T. M., Wood, M. R., Niswender, C. M., Lindsley, C. W., and Conn, P. J. (2012) Chemical modification of the M(1) agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode. ACS Chem Neurosci<\/em> 3<\/strong>, 1025-1036<\/li>\n
                                                                                                                                                                                                                              27. Engers, D. W., Blobaum, A. L., Gogliotti, R. D., Cheung, Y. Y., Salovich, J. M., Garcia-Barrantes, P. M., Daniels, J. S., Morrison, R., Jones, C. K., Soars, M. G., Zhuo, X., Hurley, J., Macor, J. E., Bronson, J. J., Conn, P. J., Lindsley, C. W., Niswender, C. M., and Hopkins, C. R. (2016) Discovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4). ACS Chem Neurosci<\/em> 7<\/strong>, 1192-1200<\/li>\n
                                                                                                                                                                                                                              28. Engers, D. W., Field, J. R., Le, U., Zhou, Y., Bolinger, J. D., Zamorano, R., Blobaum, A. L., Jones, C. K., Jadhav, S., Weaver, C. D., Conn, P. J., Lindsley, C. W., Niswender, C. M., and Hopkins, C. R. (2011) Discovery, synthesis, and structure-activity relationship development of a series of N-(4-acetamido)phenylpicolinamides as positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu(4)) with CNS exposure in rats. J Med Chem<\/em> 54<\/strong>, 1106-1110<\/li>\n
                                                                                                                                                                                                                              29. Engers, D. W., Gentry, P. R., Williams, R., Bolinger, J. D., Weaver, C. D., Menon, U. N., Conn, P. J., Lindsley, C. W., Niswender, C. M., and Hopkins, C. R. (2010) Synthesis and SAR of novel, 4-(phenylsulfamoyl)phenylacetamide mGlu4 positive allosteric modulators (PAMs) identified by functional high-throughput screening (HTS). Bioorg Med Chem Lett<\/em> 20<\/strong>, 5175-5178<\/li>\n
                                                                                                                                                                                                                              30. Engers, D. W., Jones, C. K., Bubser, M., Thompson, A. D., Blobaum, A. L., Sheffler, D. J., Zamorano, R., Carrington, S. J. S., Bridges, T. M., Morrison, R. D., Daniels, J. S., Conn, P. J., Lindsley, C. W., Niswender, C. M., and Hopkins, C. R. (2010) Discovery of a novel metabotropic glutamate receptor 4 (mGlu4) positive allosteric modulator (PAM) extended probe: Characterization of ML292, a potent and selective mGlu4 PAM which produces efficacy alone or in combination with L-DOPA in preclinical rodent models of Parkinson’s disease.<\/li>\n
                                                                                                                                                                                                                              31. Engers, D. W., Niswender, C. M., Weaver, C. D., Jadhav, S., Menon, U. N., Zamorano, R., Conn, P. J., Lindsley, C. W., and Hopkins, C. R. (2009) Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs). J Med Chem<\/em> 52<\/strong>, 4115-4118<\/li>\n
                                                                                                                                                                                                                              32. Engers, J. L., Rodriguez, A. L., Konkol, L. C., Morrison, R. D., Thompson, A. D., Byers, F. W., Blobaum, A. L., Chang, S., Venable, D. F., Loch, M. T., Niswender, C. M., Daniels, J. S., Jones, C. K., Conn, P. J., Lindsley, C. W., and Emmitte, K. A. (2015) Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents. J Med Chem<\/em> 58<\/strong>, 7485-7500<\/li>\n
                                                                                                                                                                                                                              33. Felts, A. S., Rodriguez, A. L., Blobaum, A. L., Morrison, R. D., Bates, B. S., Thompson Gray, A., Rook, J. M., Tantawy, M. N., Byers, F. W., Chang, S., Venable, D. F., Luscombe, V. B., Tamagnan, G. D., Niswender, C. M., Daniels, J. S., Jones, C. K., Conn, P. J., Lindsley, C. W., and Emmitte, K. A. (2017) Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation. J Med Chem<\/em> 60<\/strong>, 5072-5085<\/li>\n
                                                                                                                                                                                                                              34. Felts, A. S., Rodriguez, A. L., Morrison, R. D., Venable, D. F., Blobaum, A. L., Byers, F. W., Daniels, J. S., Niswender, C. M., Jones, C. K., Conn, P. J., Lindsley, C. W., and Emmitte, K. A. (2016) N-Alkylpyrido[1′,2′:1,5]pyrazolo-[4,3-d]pyrimidin-4-amines: A new series of negative allosteric modulators of mGlu1\/5 with CNS exposure in rodents. Bioorg Med Chem Lett<\/em> 26<\/strong>, 1894-1900<\/li>\n
                                                                                                                                                                                                                              35. Felts, A. S., Rodriguez, A. L., Morrison, R. D., Venable, D. F., Manka, J. T., Bates, B. S., Blobaum, A. L., Byers, F. W., Daniels, J. S., Niswender, C. M., Jones, C. K., Conn, P. J., Lindsley, C. W., and Emmitte, K. A. (2013) Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. Bioorg Med Chem Lett<\/em> 23<\/strong>, 5779-5785<\/li>\n
                                                                                                                                                                                                                              36. Felts, A. S., Rodriguez, A. L., Smith, K. A., Engers, J. L., Morrison, R. D., Byers, F. W., Blobaum, A. L., Locuson, C. W., Chang, S., Venable, D. F., Niswender, C. M., Daniels, J. S., Conn, P. J., Lindsley, C. W., and Emmitte, K. A. (2015) Design of 4-Oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides as Selective Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 2. J Med Chem<\/em> 58<\/strong>, 9027-9040<\/li>\n
                                                                                                                                                                                                                              37. Foster, D. J., Gentry, P. R., Lizardi-Ortiz, J. E., Bridges, T. M., Wood, M. R., Niswender, C. M., Sulzer, D., Lindsley, C. W., Xiang, Z., and Conn, P. J. (2014) M5 receptor activation produces opposing physiological outcomes in dopamine neurons depending on the receptor’s location. J Neurosci<\/em> 34<\/strong>, 3253-3262<\/li>\n
                                                                                                                                                                                                                              38. Foster, D. J., Wilson, J. M., Remke, D. H., Mahmood, M. S., Uddin, M. J., Wess, J., Patel, S., Marnett, L. J., Niswender, C. M., Jones, C. K., Xiang, Z., Lindsley, C. W., Rook, J. M., and Conn, P. J. (2016) Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release. Neuron<\/em> 91<\/strong>, 1244-1252<\/li>\n
                                                                                                                                                                                                                              39. Garcia, R. C., Dati, L. M., Torres, L. H., da Silva, M. A., Udo, M. S., Abdalla, F. M., da Costa, J. L., Gorjao, R., Afeche, S. C., Yonamine, M., Niswender, C. M., Conn, P. J., Camarini, R., Sandoval, M. R., and Marcourakis, T. (2015) M1 and M3 muscarinic receptors may play a role in the neurotoxicity of anhydroecgonine methyl ester, a cocaine pyrolysis product. Sci Rep<\/em> 5<\/strong>, 17555<\/li>\n
                                                                                                                                                                                                                              40. Garcia-Barrantes, P. M., Cho, H. P., Blobaum, A. L., Niswender, C. M., Conn, P. J., and Lindsley, C. W. (2015) Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 1: SAR of modifications to the central aryl core. Bioorg Med Chem Lett<\/em> 25<\/strong>, 5107-5110<\/li>\n
                                                                                                                                                                                                                              41. Garcia-Barrantes, P. M., Cho, H. P., Blobaum, A. L., Niswender, C. M., Conn, P. J., and Lindsley, C. W. (2016) Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 3. Engineering plasma stability by discovery and optimization of isoindolinone analogs. Bioorg Med Chem Lett<\/em> 26<\/strong>, 1869-1872<\/li>\n
                                                                                                                                                                                                                              42. Garcia-Barrantes, P. M., Cho, H. P., Metts, A. M., Blobaum, A. L., Niswender, C. M., Conn, P. J., and Lindsley, C. W. (2016) Lead optimization of the VU0486321 series of mGlu(1) PAMs. Part 2: SAR of alternative 3-methyl heterocycles and progress towards an in vivo tool. Bioorg Med Chem Lett<\/em> 26<\/strong>, 751-756<\/li>\n
                                                                                                                                                                                                                              43. Garcia-Barrantes, P. M., Cho, H. P., Niswender, C. M., Byers, F. W., Locuson, C. W., Blobaum, A. L., Xiang, Z., Rook, J. M., Conn, P. J., and Lindsley, C. W. (2015) Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics. J Med Chem<\/em> 58<\/strong>, 7959-7971<\/li>\n
                                                                                                                                                                                                                              44. Garcia-Barrantes, P. M., Cho, H. P., Starr, T. M., Blobaum, A. L., Niswender, C. M., Conn, P. J., and Lindsley, C. W. (2016) Re-exploration of the mGlu1 PAM Ro 07-11401 scaffold: Discovery of analogs with improved CNS penetration despite steep SAR. Bioorg Med Chem Lett<\/em> 26<\/strong>, 2289-2292<\/li>\n
                                                                                                                                                                                                                              45. Gentry, P. R., Bridges, T. M., Daniels, J. S., Lamsal, A., Vinson, P. N., Niswender, C. M., Hodder, P. S., Rosen, H., Conn, P. J., Engers, J., Lindsley, C. W., and Wood, M. R. (2010) Development and characterization of a highly selective M5 PAM probe molecule with improved potency.<\/li>\n
                                                                                                                                                                                                                              46. Gentry, P. R., Bridges, T. M., Lamsal, A., Vinson, P. N., Smith, E., Chase, P., Hodder, P. S., Engers, J. L., Niswender, C. M., Daniels, J. S., Conn, P. J., Wood, M. R., and Lindsley, C. W. (2013) Discovery of ML326: The first sub-micromolar, selective M5 PAM. Bioorg Med Chem Lett<\/em> 23<\/strong>, 2996-3000<\/li>\n
                                                                                                                                                                                                                              47. Gentry, P. R., Kokubo, M., Bridges, T. M., Cho, H. P., Smith, E., Chase, P., Hodder, P. S., Utley, T. J., Rajapakse, A., Byers, F., Niswender, C. M., Morrison, R. D., Daniels, J. S., Wood, M. R., Conn, P. J., and Lindsley, C. W. (2014) Discovery, synthesis and characterization of a highly muscarinic acetylcholine receptor (mAChR)-selective M5-orthosteric antagonist, VU0488130 (ML381): a novel molecular probe. ChemMedChem<\/em> 9<\/strong>, 1677-1682<\/li>\n
                                                                                                                                                                                                                              48. Gentry, P. R., Kokubo, M., Bridges, T. M., Daniels, J. S., Niswender, C. M., Smith, E., Chase, P., Hodder, P. S., Rosen, H., Conn, P. J., Engers, J., Brewer, K. A., Lindsley, C. W., and Wood, M. R. (2010) Development of the First CNS penetrant M5 Positive Allosteric Modulator (PAM) Based on a Novel, non-Isatin Core.<\/li>\n
                                                                                                                                                                                                                              49. Gentry, P. R., Kokubo, M., Bridges, T. M., Daniels, J. S., Niswender, C. M., Smith, E., Chase, P., Hodder, P. S., Rosen, H., Conn, P. J., Engers, J., Brewer, K. A., Wood, M. R., and Lindsley, C. W. (2010) Development of a Novel, Orthosteric M5 Antagonist Possessing a High Degree of Muscarinic Subtype Selectivity.<\/li>\n
                                                                                                                                                                                                                              50. Gentry, P. R., Kokubo, M., Bridges, T. M., Daniels, J. S., Niswender, C. M., Smith, E., Chase, P., Hodder, P. S., Rosen, H., Conn, P. J., Engers, J., Brewer, K. A., Wood, M. R., and Lindsley, C. W. (2010) Development of the First Potent, Selective and CNS penetrant M5 Negative Allosteric Modulator (NAM).<\/li>\n
                                                                                                                                                                                                                              51. Gentry, P. R., Kokubo, M., Bridges, T. M., Kett, N. R., Harp, J. M., Cho, H. P., Smith, E., Chase, P., Hodder, P. S., Niswender, C. M., Daniels, J. S., Conn, P. J., Wood, M. R., and Lindsley, C. W. (2013) Discovery of the first M5-selective and CNS penetrant negative allosteric modulator (NAM) of a muscarinic acetylcholine receptor: (S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoi ndol-5(9bH)-one (ML375). J Med Chem<\/em> 56<\/strong>, 9351-9355<\/li>\n
                                                                                                                                                                                                                              52. Gentry, P. R., Kokubo, M., Bridges, T. M., Noetzel, M. J., Cho, H. P., Lamsal, A., Smith, E., Chase, P., Hodder, P. S., Niswender, C. M., Daniels, J. S., Conn, P. J., Lindsley, C. W., and Wood, M. R. (2014) Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4- carboxamide (ML380). J Med Chem<\/em> 57<\/strong>, 7804-7810<\/li>\n
                                                                                                                                                                                                                              53. Ghoshal, A., Rook, J. M., Dickerson, J. W., Roop, G. N., Morrison, R. D., Jalan-Sakrikar, N., Lamsal, A., Noetzel, M. J., Poslusney, M. S., Wood, M. R., Melancon, B. J., Stauffer, S. R., Xiang, Z., Daniels, J. S., Niswender, C. M., Jones, C. K., Lindsley, C. W., and Conn, P. J. (2016) Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model. Neuropsychopharmacology<\/em> 41<\/strong>, 598-610<\/li>\n
                                                                                                                                                                                                                              54. Gogliotti, R. D., Blobaum, A. L., Morrison, R. M., Daniels, J. S., Salovich, J. M., Cheung, Y. Y., Rodriguez, A. L., Loch, M. T., Conn, P. J., Lindsley, C. W., Niswender, C. M., and Hopkins, C. R. (2016) Discovery and characterization of a novel series of N-phenylsulfonyl-1H-pyrrole picolinamides as positive allosteric modulators of the metabotropic glutamate receptor 4 (mGlu4). Bioorg Med Chem Lett<\/em> 26<\/strong>, 2984-2987<\/li>\n
                                                                                                                                                                                                                              55. Gogliotti, R. D., Engers, D. W., Garcia-Barrantes, P. M., Panarese, J. D., Gentry, P. R., Blobaum, A. L., Morrison, R. D., Daniels, J. S., Thompson, A. D., Jones, C. K., Conn, P. J., Niswender, C. M., Lindsley, C. W., and Hopkins, C. R. (2016) Discovery of 3-aminopicolinamides as metabotropic glutamate receptor subtype 4 (mGlu4) positive allosteric modulator warheads engendering CNS exposure and in vivo efficacy. Bioorg Med Chem Lett<\/em> 26<\/strong>, 2915-2919<\/li>\n
                                                                                                                                                                                                                              56. Gogliotti, R. G., Fisher, N. M., Stansley, B., Jones, C. K., Lindsley, C. W., Conn, P. J., and Niswender, C. M. (Submitted) Total RNA-sequencing of Rett syndrome autposy samples reveals conserved disruption of autism-associated genes and identified the M4 muscarinic receptor as a novel therapeutic target.<\/li>\n
                                                                                                                                                                                                                              57. Gogliotti, R. G., Senter, R. K., Fisher, N. M., Adams, J. J., Zamorano, R., Walker, A. G., Blobaum, A. L., Engers, D. W., Hopkins, C. R., Daniels, J. S., Jones, C. K., Lindsley, C. W., Xiang, Z., Conn, P. J., and Niswender, C. M. (In press) Metabotropic glutamate receptor 7 allosteric modulation rescues long term potentiation, cognition, and apneas in Mecp2-deficient mice. Sci Trans Med<\/em><\/li>\n
                                                                                                                                                                                                                              58. Gogliotti, R. G., Senter, R. K., Rook, J. M., Ghoshal, A., Zamorano, R., Malosh, C., Stauffer, S. R., Bridges, T. M., Bartolome, J. M., Daniels, J. S., Jones, C. K., Lindsley, C. W., Conn, P. J., and Niswender, C. M. (2016) mGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome. Hum Mol Genet<\/em> 25<\/strong>, 1990-2004<\/li>\n
                                                                                                                                                                                                                              59. Gould, R. W., Amato, R. J., Bubser, M., Joffe, M. E., Nedelcovych, M. T., Thompson, A. D., Nickols, H. H., Yuh, J. P., Zhan, X., Felts, A. S., Rodriguez, A. L., Morrison, R. D., Byers, F. W., Rook, J. M., Daniels, J. S., Niswender, C. M., Conn, P. J., Emmitte, K. A., Lindsley, C. W., and Jones, C. K. (2016) Partial mGlu(5) Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects. Neuropsychopharmacology<\/em> 41<\/strong>, 1166-1178<\/li>\n
                                                                                                                                                                                                                              60. Gould, R. W., Grannan, M. D., Gunter, B. W., Ball, J., Bubser, M., Bridges, T. M., Wess, J., Wood, M. W., Brandon, N. J., Duggan, M. E., Niswender, C. M., Lindsley, C. W., Conn, P. J., and Jones, C. K. (2017) Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M4 PAM VU0467154. Neuropharmacology<\/em><\/li>\n
                                                                                                                                                                                                                              61. Gould, R. W., Nedelcovych, M. T., Gong, X., Tsai, E., Bubser, M., Bridges, T. M., Wood, M. R., Duggan, M. E., Brandon, N. J., Dunlop, J., Wood, M. W., Ivarsson, M., Noetzel, M. J., Daniels, J. S., Niswender, C. M., Lindsley, C. W., Conn, P. J., and Jones, C. K. (2016) State-dependent alterations in sleep\/wake architecture elicited by the M4 PAM VU0467154 – Relation to antipsychotic-like drug effects. Neuropharmacology<\/em> 102<\/strong>, 244-253<\/li>\n
                                                                                                                                                                                                                              62. Grannan, M. D., Mielnik, C. A., Moran, S. P., Gould, R. W., Ball, J., Lu, Z., Bubser, M., Ramsey, A. J., Abe, M., Cho, H. P., Nance, K. D., Blobaum, A. L., Niswender, C. M., Conn, P. J., Lindsley, C. W., and Jones, C. K. (2016) Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M1 PAM VU6004256. ACS Chem Neurosci<\/em> 7<\/strong>, 1706-1716<\/li>\n
                                                                                                                                                                                                                              63. Gregory, K. J., Herman, E. J., Ramsey, A. J., Hammond, A. S., Byun, N. E., Stauffer, S. R., Manka, J. T., Jadhav, S., Bridges, T. M., Weaver, C. D., Niswender, C. M., Steckler, T., Drinkenburg, W. H., Ahnaou, A., Lavreysen, H., Macdonald, G. J., Bartolome, J. M., Mackie, C., Hrupka, B. J., Caron, M. G., Daigle, T. L., Lindsley, C. W., Conn, P. J., and Jones, C. K. (2013) N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement. J Pharmacol Exp Ther<\/em> 347<\/strong>, 438-457<\/li>\n
                                                                                                                                                                                                                              64. Gregory, K. J., Malosh, C., Turlington, M., Morrison, R., Vinson, P., Daniels, J. S., Jones, C., Niswender, C. M., Conn, P. J., Lindsley, C. W., and Stauffer, S. R. (2010) Identification of a high affinity MPEP-site silent allosteric modulator (SAM) for the metabotropic glutamate subtype 5 receptor (mGlu5).<\/li>\n
                                                                                                                                                                                                                              65. Gregory, K. J., Noetzel, M. J., and Niswender, C. M. (2013) Pharmacology of metabotropic glutamate receptor allosteric modulators: structural basis and therapeutic potential for CNS disorders. Prog Mol Biol Transl Sci<\/em> 115<\/strong>, 61-121<\/li>\n
                                                                                                                                                                                                                              66. Gregory, K. J., Noetzel, M. J., Rook, J. M., Vinson, P. N., Stauffer, S. R., Rodriguez, A. L., Emmitte, K. A., Zhou, Y., Chun, A. C., Felts, A. S., Chauder, B. A., Lindsley, C. W., Niswender, C. M., and Conn, P. J. (2012) Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships. Mol Pharmacol<\/em> 82<\/strong>, 860-875<\/li>\n
                                                                                                                                                                                                                              67. Hagley, M. T., Hulisz, D. T., and Burns, C. M. (1993) Hepatotoxicity associated with angiotensin-converting enzyme inhibitors. Ann Pharmacother<\/em> 27<\/strong>, 228-231<\/li>\n
                                                                                                                                                                                                                              68. Hammond, A. S., Rodriguez, A. L., Townsend, S. D., Niswender, C. M., Gregory, K. J., Lindsley, C. W., and Conn, P. J. (2010) Discovery of a Novel Chemical Class of mGlu(5) Allosteric Ligands with Distinct Modes of Pharmacology. ACS Chem Neurosci<\/em> 1<\/strong>, 702-716<\/li>\n
                                                                                                                                                                                                                              69. Han, C., Chatterjee, A., Noetzel, M. J., Panarese, J. D., Smith, E., Chase, P., Hodder, P., Niswender, C., Conn, P. J., Lindsley, C. W., and Stauffer, S. R. (2015) Discovery and SAR of muscarinic receptor subtype 1 (M1) allosteric activators from a molecular libraries high throughput screen. Part 1: 2,5-dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones as positive allosteric modulators. Bioorg Med Chem Lett<\/em> 25<\/strong>, 384-388<\/li>\n
                                                                                                                                                                                                                              70. Hemstapat, K., Da Costa, H., Nong, Y., Brady, A. E., Luo, Q., Niswender, C. M., Tamagnan, G. D., and Conn, P. J. (2007) A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. J Pharmacol Exp Ther<\/em> 322<\/strong>, 254-264<\/li>\n
                                                                                                                                                                                                                              71. Herrick-Davis, K., Grinde, E., and Niswender, C. M. (1999) Serotonin 5-HT2C receptor RNA editing alters receptor basal activity: implications for serotonergic signal transduction. J Neurochem<\/em> 73<\/strong>, 1711-1717<\/li>\n
                                                                                                                                                                                                                              72. Hinko, C. N., Crider, A. M., Kliem, M. A., Steinmiller, C. L., Seo, T. H., Ho, B., Venkatarangan, P., el-Assadi, A. A., Chang, H., Burns, C. M., Tietz, E. I., Andersen, P. H., and Klitgaard, H. (1996) Anticonvulsant activity of novel derivatives of 2- and 3-piperidinecarboxylic acid in mice and rats. Neuropharmacology<\/em> 35<\/strong>, 1721-1735<\/li>\n
                                                                                                                                                                                                                              73. Hopkins, C. R., Engers, D. W., Niswender, C. M., Jones, C. K., Dawson, E., Weaver, C. D., Daniels, J. S., Conn, P. J., and Lindsley, C. W. (2010) Discovery of a potent, selective and orally active in vivo mGlu4 positive allosteric modulator.<\/li>\n
                                                                                                                                                                                                                              74. Hopkins, C. R., Lindsley, C. W., and Niswender, C. M. (2009) mGluR4-positive allosteric modulation as potential treatment for Parkinson’s disease. Future Med Chem<\/em> 1<\/strong>, 501-513<\/li>\n
                                                                                                                                                                                                                              75. Hopkins, C. R., Niswender, C. M., Lewis, L. M., Weaver, C. D., and Lindsley, C. W. (2010) Discovery of a potent, selective and in vivo active mGluR4 positive allosteric modulator.<\/li>\n
                                                                                                                                                                                                                              76. Iderberg, H., Maslava, N., Thompson, A. D., Bubser, M., Niswender, C. M., Hopkins, C. R., Lindsley, C. W., Conn, P. J., Jones, C. K., and Cenci, M. A. (2015) Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson’s disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist. Neuropharmacology<\/em> 95<\/strong>, 121-129<\/li>\n
                                                                                                                                                                                                                              77. Jalan-Sakrikar, N., Field, J. R., Klar, R., Mattmann, M. E., Gregory, K. J., Zamorano, R., Engers, D. W., Bollinger, S. R., Weaver, C. D., Days, E. L., Lewis, L. M., Utley, T. J., Hurtado, M., Rigault, D., Acher, F., Walker, A. G., Melancon, B. J., Wood, M. R., Lindsley, C. W., Conn, P. J., Xiang, Z., Hopkins, C. R., and Niswender, C. M. (2014) Identification of positive allosteric modulators VU0155094 (ML397) and VU0422288 (ML396) reveals new insights into the biology of metabotropic glutamate receptor 7. ACS Chem Neurosci<\/em> 5<\/strong>, 1221-1237<\/li>\n
                                                                                                                                                                                                                              78. Jalan-Sakrikar, N., Roper-Field, J., Klar, R., Mattman, M., Walker, A. G., Zamorano, R., Xiang, Z., Byers, C. F., Blobaum, A. L., Engers, D., Weaver, C. D., Days, E., Utley, T. J., Melancon, B., Daniels, J. S., Wood, M. R., Lindsley, C. W., Conn, P. J., Hopkins, C. R., and Niswender, C. M. (2010) The discovery and characterization of a centrally penetrant (ML396) and a peripherally restricted (ML397) pan-Group III mGlu positive allosteric modulators.<\/li>\n
                                                                                                                                                                                                                              79. Johnson, K. A., Conn, P. J., and Niswender, C. M. (2009) Glutamate receptors as therapeutic targets for Parkinson’s disease. CNS Neurol Disord Drug Targets<\/em> 8<\/strong>, 475-491<\/li>\n
                                                                                                                                                                                                                              80. Johnson, K. A., Jones, C. K., Tantawy, M. N., Bubser, M., Marvanova, M., Ansari, M. S., Baldwin, R. M., Conn, P. J., and Niswender, C. M. (2013) The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson’s disease. Neuropharmacology<\/em> 66<\/strong>, 187-195<\/li>\n
                                                                                                                                                                                                                              81. Johnson, K. A., Niswender, C. M., Conn, P. J., and Xiang, Z. (2011) Activation of group II metabotropic glutamate receptors induces long-term depression of excitatory synaptic transmission in the substantia nigra pars reticulata. Neurosci Lett<\/em> 504<\/strong>, 102-106<\/li>\n
                                                                                                                                                                                                                              82. Jones, C. K., Bubser, M., Thompson, A. D., Dickerson, J. W., Turle-Lorenzo, N., Amalric, M., Blobaum, A. L., Bridges, T. M., Morrison, R. D., Jadhav, S., Engers, D. W., Italiano, K., Bode, J., Daniels, J. S., Lindsley, C. W., Hopkins, C. R., Conn, P. J., and Niswender, C. M. (2012) The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson’s disease. J Pharmacol Exp Ther<\/em> 340<\/strong>, 404-421<\/li>\n
                                                                                                                                                                                                                              83. Jones, C. K., Engers, D. W., Thompson, A. D., Field, J. R., Blobaum, A. L., Lindsley, S. R., Zhou, Y., Gogliotti, R. D., Jadhav, S., Zamorano, R., Bogenpohl, J., Smith, Y., Morrison, R., Daniels, J. S., Weaver, C. D., Conn, P. J., Lindsley, C. W., Niswender, C. M., and Hopkins, C. R. (2011) Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model. J Med Chem<\/em> 54<\/strong>, 7639-7647<\/li>\n
                                                                                                                                                                                                                              84. Jones, C. K., Sheffler, D. J., Williams, R., Jadhav, S. B., Felts, A. S., Morrison, R. D., Niswender, C. M., Daniels, J. S., Conn, P. J., and Lindsley, C. W. (2014) Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: development of a potent and CNS penetrant [3.1.0]-based lead. Bioorg Med Chem Lett<\/em> 24<\/strong>, 1067-1070<\/li>\n
                                                                                                                                                                                                                              85. Kaufmann, K., Romaine, I., Days, E., Pascual, C., Malik, A., Yang, L., Zou, B., Du, Y., Sliwoski, G., Morrison, R. D., Denton, J., Niswender, C. M., Daniels, J. S., Sulikowski, G. A., Xie, X. S., Lindsley, C. W., and Weaver, C. D. (2013) ML297 (VU0456810), the first potent and selective activator of the GIRK potassium channel, displays antiepileptic properties in mice. ACS Chem Neurosci<\/em> 4<\/strong>, 1278-1286<\/li>\n
                                                                                                                                                                                                                              86. Klar, R., Walker, A. G., Ghose, D., Grueter, B. A., Engers, D. W., Hopkins, C. R., Lindsley, C. W., Xiang, Z., Conn, P. J., and Niswender, C. M. (2015) Activation of Metabotropic Glutamate Receptor 7 Is Required for Induction of Long-Term Potentiation at SC-CA1 Synapses in the Hippocampus. J Neurosci<\/em> 35<\/strong>, 7600-7615<\/li>\n
                                                                                                                                                                                                                              87. Klein, M. T., Vinson, P. N., and Niswender, C. M. (2013) Approaches for probing allosteric interactions at 7 transmembrane spanning receptors. Prog Mol Biol Transl Sci<\/em> 115<\/strong>, 1-59<\/li>\n
                                                                                                                                                                                                                              88. Kurata, H., Gentry, P. R., Kokubo, M., Cho, H. P., Bridges, T. M., Niswender, C. M., Byers, F. W., Wood, M. R., Daniels, J. S., Conn, P. J., and Lindsley, C. W. (2015) Further optimization of the M5 NAM MLPCN probe ML375: tactics and challenges. Bioorg Med Chem Lett<\/em> 25<\/strong>, 690-694<\/li>\n
                                                                                                                                                                                                                              89. Lamb, J. P., Engers, D. W., Niswender, C. M., Rodriguez, A. L., Venable, D. F., Conn, P. J., and Lindsley, C. W. (2011) Discovery of molecular switches within the ADX-47273 mGlu5 PAM scaffold that modulate modes of pharmacology to afford potent mGlu5 NAMs, PAMs and partial antagonists. Bioorg Med Chem Lett<\/em> 21<\/strong>, 2711-2714<\/li>\n
                                                                                                                                                                                                                              90. Le, U., Melancon, B. J., Bridges, T. M., Vinson, P. N., Utley, T. J., Lamsal, A., Rodriguez, A. L., Venable, D., Sheffler, D. J., Jones, C. K., Blobaum, A. L., Wood, M. R., Daniels, J. S., Conn, P. J., Niswender, C. M., Lindsley, C. W., and Hopkins, C. R. (2013) Discovery of a selective M(4) positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia. Bioorg Med Chem Lett<\/em> 23<\/strong>, 346-350<\/li>\n
                                                                                                                                                                                                                              91. Lebois, E. P., Bridges, T. M., Lewis, L. M., Dawson, E. S., Kane, A. S., Xiang, Z., Jadhav, S. B., Yin, H., Kennedy, J. P., Meiler, J., Niswender, C. M., Jones, C. K., Conn, P. J., Weaver, C. D., and Lindsley, C. W. (2010) Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system. ACS Chem Neurosci<\/em> 1<\/strong>, 104-121<\/li>\n
                                                                                                                                                                                                                              92. Lewis, L. M., Bridges, T. M., Niswender, C. M., Weaver, C. D., and Lindsley, C. W. (2010) Discovery of a Highly Selective in vitro and in vivo M4 Positive Allosteric Modulator (PAM).<\/li>\n
                                                                                                                                                                                                                              93. Lewis, L. M., Sheffler, D., Williams, R., Bridges, T. M., Kennedy, J. P., Brogan, J. T., Mulder, M. J., Williams, L., Nalywajko, N. T., Niswender, C. M., Weaver, C. D., Conn, P. J., and Lindsley, C. W. (2008) Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists. Bioorg Med Chem Lett<\/em> 18<\/strong>, 885-890<\/li>\n
                                                                                                                                                                                                                              94. Lindsley, C. W., Emmitte, K. A., Hopkins, C. R., Bridges, T. M., Gregory, K. J., Niswender, C. M., and Conn, P. J. (2016) Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors. Chem Rev<\/em> 116<\/strong>, 6707-6741<\/li>\n
                                                                                                                                                                                                                              95. Lindsley, C. W., Niswender, C. M., Engers, D. W., and Hopkins, C. R. (2009) Recent progress in the development of mGluR4 positive allosteric modulators for the treatment of Parkinson’s disease. Curr Top Med Chem<\/em> 9<\/strong>, 949-963<\/li>\n
                                                                                                                                                                                                                              96. Lovell, K. M., Felts, A. S., Rodriguez, A. L., Venable, D. F., Cho, H. P., Morrison, R. D., Byers, F. W., Daniels, J. S., Niswender, C. M., Conn, P. J., Lindsley, C. W., and Emmitte, K. A. (2013) N-Acyl-N’-arylpiperazines as negative allosteric modulators of mGlu1: identification of VU0469650, a potent and selective tool compound with CNS exposure in rats. Bioorg Med Chem Lett<\/em> 23<\/strong>, 3713-3718<\/li>\n
                                                                                                                                                                                                                              97. Malosh, C., Turlington, M., Bridges, T. M., Rook, J. M., Noetzel, M. J., Vinson, P. N., Steckler, T., Lavreysen, H., Mackie, C., Bartolome-Nebreda, J. M., Conde-Ceide, S., Martinez-Viturro, C. M., Piedrafita, M., Sanchez-Casado, M. R., Macdonald, G. J., Daniels, J. S., Jones, C. K., Niswender, C. M., Conn, P. J., Lindsley, C. W., and Stauffer, S. R. (2015) Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators. Bioorg Med Chem Lett<\/em> 25<\/strong>, 5115-5120<\/li>\n
                                                                                                                                                                                                                              98. Manka, J., Zhou, Y., Chun, A., Dawson, E. S., Vinson, P. N., Niswender, C. M., Noetzel, M. J., Rook, J. M., Bridges, T. M., Daniels, J. S., Jones, C., Conn, P. J., Lindsley, C. W., and Stauffer, S. R. (2010) Identification of a Selective Allosteric Agonist of mGlu5.<\/li>\n
                                                                                                                                                                                                                              99. Manka, J. T., Rodriguez, A. L., Morrison, R. D., Venable, D. F., Cho, H. P., Blobaum, A. L., Daniels, J. S., Niswender, C. M., Conn, P. J., Lindsley, C. W., and Emmitte, K. A. (2013) Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1. Bioorg Med Chem Lett<\/em> 23<\/strong>, 5091-5096<\/li>\n
                                                                                                                                                                                                                              100. Manka, J. T., Vinson, P. N., Gregory, K. J., Zhou, Y., Williams, R., Gogi, K., Days, E., Jadhav, S., Herman, E. J., Lavreysen, H., Mackie, C., Bartolome, J. M., Macdonald, G. J., Steckler, T., Daniels, J. S., Weaver, C. D., Niswender, C. M., Jones, C. K., Conn, P. J., Lindsley, C. W., and Stauffer, S. R. (2012) Optimization of an ether series of mGlu5 positive allosteric modulators: molecular determinants of MPEP-site interaction crossover. Bioorg Med Chem Lett<\/em> 22<\/strong>, 6481-6485<\/li>\n
                                                                                                                                                                                                                              101. Marlo, J. E., Niswender, C. M., Days, E. L., Bridges, T. M., Xiang, Y., Rodriguez, A. L., Shirey, J. K., Brady, A. E., Nalywajko, T., Luo, Q., Austin, C. A., Williams, M. B., Kim, K., Williams, R., Orton, D., Brown, H. A., Lindsley, C. W., Weaver, C. D., and Conn, P. J. (2009) Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol<\/em> 75<\/strong>, 577-588<\/li>\n
                                                                                                                                                                                                                              102. Martin-Martin, M. L., Bartolome-Nebreda, J. M., Conde-Ceide, S., Alonso de Diego, S. A., Lopez, S., Martinez-Viturro, C. M., Tong, H. M., Lavreysen, H., Macdonald, G. J., Steckler, T., Mackie, C., Bridges, T. M., Daniels, J. S., Niswender, C. M., Noetzel, M. J., Jones, C. K., Conn, P. J., Lindsley, C. W., and Stauffer, S. R. (2015) Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5). Bioorg Med Chem Lett<\/em> 25<\/strong>, 1310-1317<\/li>\n
                                                                                                                                                                                                                              103. Melancon, B. J., Gogliotti, R. D., Tarr, J. C., Saleh, S. A., Chauder, B. A., Lebois, E. P., Cho, H. P., Utley, T. J., Sheffler, D. J., Bridges, T. M., Morrison, R. D., Daniels, J. S., Niswender, C. M., Conn, P. J., Lindsley, C. W., and Wood, M. R. (2012) Continued optimization of the MLPCN probe ML071 into highly potent agonists of the hM1 muscarinic acetylcholine receptor. Bioorg Med Chem Lett<\/em> 22<\/strong>, 3467-3472<\/li>\n
                                                                                                                                                                                                                              104. Melancon, B. J., Hopkins, C. R., Wood, M. R., Emmitte, K. A., Niswender, C. M., Christopoulos, A., Conn, P. J., and Lindsley, C. W. (2012) Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J Med Chem<\/em> 55<\/strong>, 1445-1464<\/li>\n
                                                                                                                                                                                                                              105. Melancon, B. J., Lamers, A. P., Bridges, T. M., Sulikowski, G. A., Utley, T. J., Sheffler, D. J., Noetzel, M. J., Morrison, R. D., Daniels, J. S., Niswender, C. M., Jones, C. K., Conn, P. J., Lindsley, C. W., and Wood, M. R. (2012) Development of a more highly selective M(1) antagonist from the continued optimization of the MLPCN Probe ML012. Bioorg Med Chem Lett<\/em> 22<\/strong>, 1044-1048<\/li>\n
                                                                                                                                                                                                                              106. Melancon, B. J., Poslusney, M. S., Gentry, P. R., Tarr, J. C., Sheffler, D. J., Mattmann, M. E., Bridges, T. M., Utley, T. J., Daniels, J. S., Niswender, C. M., Conn, P. J., Lindsley, C. W., and Wood, M. R. (2013) Isatin replacements applied to the highly selective, muscarinic M1 PAM ML137: continued optimization of an MLPCN probe molecule. Bioorg Med Chem Lett<\/em> 23<\/strong>, 412-416<\/li>\n
                                                                                                                                                                                                                              107. Melancon, B. J., Utley, T. J., Sevel, C., Mattmann, M. E., Cheung, Y. Y., Bridges, T. M., Morrison, R. D., Sheffler, D. J., Niswender, C. M., Daniels, J. S., Conn, P. J., Lindsley, C. W., and Wood, M. R. (2012) Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012. Bioorg Med Chem Lett<\/em> 22<\/strong>, 5035-5040<\/li>\n
                                                                                                                                                                                                                              108. Melancon, B. J., Wood, M. R., Noetzel, M. J., Nance, K. D., Engelberg, E. M., Han, C., Lamsal, A., Chang, S., Cho, H. P., Byers, F. W., Bubser, M., Jones, C. K., Niswender, C. M., Wood, M. W., Engers, D. W., Wu, D., Brandon, N. J., Duggan, M. E., Jeffrey Conn, P., Bridges, T. M., and Lindsley, C. W. (2017) Optimization of M4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology. Bioorg Med Chem Lett<\/em><\/li>\n
                                                                                                                                                                                                                              109. Melancon, B. J., Wood, M. R., Noetzel, M. J., Nance, K. D., Han, C., Lamsal, A., Chang, S., Cho, H. P., Byers, F. W., Bubser, M., Jones, C. K., Niswender, C. M., Wood, M. W., Engers, D. W., Brandon, N. J., Duggan, M. E., Conn, P. J., Bridges, T. M., and Lindsley, C. W. (In press) Optimization of M4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology. Bioorg Med Chem Lett<\/em><\/li>\n
                                                                                                                                                                                                                              110. Moehle, M. S., Pancani, T., Byun, N., Wilson, G. H., Dickerson, J. W., Remke, D. H., Xiang, Z., Niswender, C. M., Wess, J., Jones, C. K., Lindsley, C. W., Rook, J. M., and Conn, P. J. (Under revision) Cholinergic projections to the SNr inhibit dopamine modulation of basal ganglia motor function through activation of the M4 muscarinic receptor. Neuron<\/em><\/li>\n
                                                                                                                                                                                                                              111. Morris, L. C., Nance, K. D., Gentry, P. R., Days, E. L., Weaver, C. D., Niswender, C. M., Thompson, A. D., Jones, C. K., Locuson, C. W., Morrison, R. D., Daniels, J. S., Niswender, K. D., and Lindsley, C. W. (2014) Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-py rrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM). J Med Chem<\/em> 57<\/strong>, 10192-10197<\/li>\n
                                                                                                                                                                                                                              112. Morrison, R. D., Blobaum, A. L., Byers, F. W., Santomango, T. S., Bridges, T. M., Stec, D., Brewer, K. A., Sanchez-Ponce, R., Corlew, M. M., Rush, R., Felts, A. S., Manka, J., Bates, B. S., Venable, D. F., Rodriguez, A. L., Jones, C. K., Niswender, C. M., Conn, P. J., Lindsley, C. W., Emmitte, K. A., and Daniels, J. S. (2012) The role of aldehyde oxidase and xanthine oxidase in the biotransformation of a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5. Drug Metab Dispos<\/em> 40<\/strong>, 1834-1845<\/li>\n
                                                                                                                                                                                                                              113. Mueller, R., Dawson, E. S., Meiler, J., Rodriguez, A. L., Chauder, B. A., Bates, B. S., Felts, A. S., Lamb, J. P., Menon, U. N., Jadhav, S. B., Kane, A. S., Jones, C. K., Gregory, K. J., Niswender, C. M., Conn, P. J., Olsen, C. M., Winder, D. G., Emmitte, K. A., and Lindsley, C. W. (2012) Discovery of 2-(2-benzoxazoyl amino)-4-aryl-5-cyanopyrimidine as negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu(5)): from an artificial neural network virtual screen to an in vivo tool compound. ChemMedChem<\/em> 7<\/strong>, 406-414<\/li>\n
                                                                                                                                                                                                                              114. Mueller, R., Dawson, E. S., Niswender, C. M., Butkiewicz, M., Hopkins, C. R., Weaver, C. D., Lindsley, C. W., Conn, P. J., and Meiler, J. (2012) Iterative experimental and virtual high-throughput screening identifies metabotropic glutamate receptor subtype 4 positive allosteric modulators. J Mol Model<\/em> 18<\/strong>, 4437-4446<\/li>\n
                                                                                                                                                                                                                              115. Nance, K. D., Days, E. L., Weaver, C. D., Coldren, A., Farmer, T. D., Cho, H. P., Niswender, C. M., Blobaum, A. L., Niswender, K. D., and Lindsley, C. W. (2017) Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrim idine-2,4(1H,3H)-dione Core. J Med Chem<\/em><\/li>\n
                                                                                                                                                                                                                              116. Nickols, H. H., Yuh, J. P., Gregory, K. J., Morrison, R. D., Bates, B. S., Stauffer, S. R., Emmitte, K. A., Bubser, M., Peng, W., Nedelcovych, M. T., Thompson, A., Lv, X., Xiang, Z., Daniels, J. S., Niswender, C. M., Lindsley, C. W., Jones, C. K., and Conn, P. J. (2016) VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy. J Pharmacol Exp Ther<\/em> 356<\/strong>, 123-136<\/li>\n
                                                                                                                                                                                                                              117. Niswender, C. M. (1998) Recent advances in mammalian RNA editing. Cell Mol Life Sci<\/em> 54<\/strong>, 946-964<\/li>\n
                                                                                                                                                                                                                              118. Niswender, C. M. (2002) Strategies and requirements for the detection of RNA editing in G protein coupled-receptor RNA. Methods Enzymol<\/em> 343<\/strong>, 476-492<\/li>\n
                                                                                                                                                                                                                              119. Niswender, C. M., and Conn, P. J. (2010) Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol<\/em> 50<\/strong>, 295-322<\/li>\n
                                                                                                                                                                                                                              120. Niswender, C. M., Copeland, S. C., Herrick-Davis, K., Emeson, R. B., and Sanders-Bush, E. (1999) RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J Biol Chem<\/em> 274<\/strong>, 9472-9478<\/li>\n
                                                                                                                                                                                                                              121. Niswender, C. M., Herrick-Davis, K., Dilley, G. E., Meltzer, H. Y., Overholser, J. C., Stockmeier, C. A., Emeson, R. B., and Sanders-Bush, E. (2001) RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy. Neuropsychopharmacology<\/em> 24<\/strong>, 478-491<\/li>\n
                                                                                                                                                                                                                              122. Niswender, C. M., Ishihara, R. W., Judge, L. M., Zhang, C., Shokat, K. M., and McKnight, G. S. (2002) Protein engineering of protein kinase A catalytic subunits results in the acquisition of novel inhibitor sensitivity. J Biol Chem<\/em> 277<\/strong>, 28916-28922<\/li>\n
                                                                                                                                                                                                                              123. Niswender, C. M., Johnson, K. A., Luo, Q., Ayala, J. E., Kim, C., Conn, P. J., and Weaver, C. D. (2008) A novel assay of Gi\/o-linked G protein-coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors. Mol Pharmacol<\/em> 73<\/strong>, 1213-1224<\/li>\n
                                                                                                                                                                                                                              124. Niswender, C. M., Johnson, K. A., Miller, N. R., Ayala, J. E., Luo, Q., Williams, R., Saleh, S., Orton, D., Weaver, C. D., and Conn, P. J. (2010) Context-dependent pharmacology exhibited by negative allosteric modulators of metabotropic glutamate receptor 7. Mol Pharmacol<\/em> 77<\/strong>, 459-468<\/li>\n
                                                                                                                                                                                                                              125. Niswender, C. M., Johnson, K. A., Weaver, C. D., Jones, C. K., Xiang, Z., Luo, Q., Rodriguez, A. L., Marlo, J. E., de Paulis, T., Thompson, A. D., Days, E. L., Nalywajko, T., Austin, C. A., Williams, M. B., Ayala, J. E., Williams, R., Lindsley, C. W., and Conn, P. J. (2008) Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol<\/em> 74<\/strong>, 1345-1358<\/li>\n
                                                                                                                                                                                                                              126. Niswender, C. M., Jones, C. K., and Conn, P. J. (2005) New therapeutic frontiers for metabotropic glutamate receptors. Curr Top Med Chem<\/em> 5<\/strong>, 847-857<\/li>\n
                                                                                                                                                                                                                              127. Niswender, C. M., Jones, C. K., Lin, X., Bubser, M., Thompson Gray, A., Blobaum, A. L., Engers, D. W., Rodriguez, A. L., Loch, M. T., Daniels, J. S., Lindsley, C. W., Hopkins, C. R., Javitch, J. A., and Conn, P. J. (2016) Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2\/4 Heteromers. ACS Chem Neurosci<\/em> 7<\/strong>, 1201-1211<\/li>\n
                                                                                                                                                                                                                              128. Niswender, C. M., Lebois, E. P., Luo, Q., Kim, K., Muchalski, H., Yin, H., Conn, P. J., and Lindsley, C. W. (2008) Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel mGluR4 positive allosteric modulators. Bioorg Med Chem Lett<\/em> 18<\/strong>, 5626-5630<\/li>\n
                                                                                                                                                                                                                              129. Niswender, C. M., Rodriguez, A. L., Sheffler, D. J., Utley, T. J., Vinson, P. N., Dawson, E. S., Jones, C. K., Wood, M. R., Daniels, J. S., Conn, P. J., Engers, J. L., Le, U. M., Melancon, B. J., Hopkins, C. R., and Lindsley, C. W. (2010) Extended Probe Characterization: Development of an M4 PAM with Improved Activity and Brain Exposure, while Avoiding Species Bias.<\/li>\n
                                                                                                                                                                                                                              130. Niswender, C. M., Sanders-Bush, E., and Emeson, R. B. (1998) Identification and characterization of RNA editing events within the 5-HT2C receptor. Ann N Y Acad Sci<\/em> 861<\/strong>, 38-48<\/li>\n
                                                                                                                                                                                                                              131. Niswender, C. M., Willis, B. S., Wallen, A., Sweet, I. R., Jetton, T. L., Thompson, B. R., Wu, C., Lange, A. J., and McKnight, G. S. (2005) Cre recombinase-dependent expression of a constitutively active mutant allele of the catalytic subunit of protein kinase A. Genesis<\/em> 43<\/strong>, 109-119<\/li>\n
                                                                                                                                                                                                                              132. Noetzel, M. J., Gregory, K. J., Vinson, P. N., Manka, J. T., Stauffer, S. R., Lindsley, C. W., Niswender, C. M., Xiang, Z., and Conn, P. J. (2013) A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling. Mol Pharmacol<\/em> 83<\/strong>, 835-847<\/li>\n
                                                                                                                                                                                                                              133. Noetzel, M. J., Rook, J. M., Vinson, P. N., Cho, H. P., Days, E., Zhou, Y., Rodriguez, A. L., Lavreysen, H., Stauffer, S. R., Niswender, C. M., Xiang, Z., Daniels, J. S., Jones, C. K., Lindsley, C. W., Weaver, C. D., and Conn, P. J. (2012) Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. Mol Pharmacol<\/em> 81<\/strong>, 120-133<\/li>\n
                                                                                                                                                                                                                              134. Panarese, J. D., Cho, H. P., Adams, J. J., Nance, K. D., Garcia-Barrantes, P. M., Chang, S., Morrison, R. D., Blobaum, A. L., Niswender, C. M., Stauffer, S. R., Conn, P. J., and Lindsley, C. W. (2016) Further optimization of the M1 PAM VU0453595: Discovery of novel heterobicyclic core motifs with improved CNS penetration. Bioorg Med Chem Lett<\/em> 26<\/strong>, 3822-3825<\/li>\n
                                                                                                                                                                                                                              135. Pancani, T., Foster, D. J., Moehle, M. S., Bichell, T. J., Bradley, E., Bridges, T. M., Klar, R., Poslusney, M., Rook, J. M., Daniels, J. S., Niswender, C. M., Jones, C. K., Wood, M. R., Bowman, A. B., Lindsley, C. W., Xiang, Z., and Conn, P. J. (2015) Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice. Proc Natl Acad Sci U S A<\/em> 112<\/strong>, 14078-14083<\/li>\n
                                                                                                                                                                                                                              136. Ponnazhagan, R., Harms, A. S., Thome, A. D., Jurkuvenaite, A., Gogliotti, R., Niswender, C. M., Conn, P. J., and Standaert, D. G. (2016) The Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator ADX88178 Inhibits Inflammatory Responses in Primary Microglia. J Neuroimmune Pharmacol<\/em> 11<\/strong>, 231-237<\/li>\n
                                                                                                                                                                                                                              137. Poslusney, M. S., Melancon, B. J., Gentry, P. R., Sheffler, D. J., Bridges, T. M., Utley, T. J., Daniels, J. S., Niswender, C. M., Conn, P. J., Lindsley, C. W., and Wood, M. R. (2013) Spirocyclic replacements for the isatin in the highly selective, muscarinic M1 PAM ML137: the continued optimization of an MLPCN probe molecule. Bioorg Med Chem Lett<\/em> 23<\/strong>, 1860-1864<\/li>\n
                                                                                                                                                                                                                              138. Poslusney, M. S., Sevel, C., Utley, T. J., Bridges, T. M., Morrison, R. D., Kett, N. R., Sheffler, D. J., Niswender, C. M., Daniels, J. S., Conn, P. J., Lindsley, C. W., and Wood, M. R. (2012) Synthesis and biological characterization of a series of novel diaryl amide M(1) antagonists. Bioorg Med Chem Lett<\/em> 22<\/strong>, 6923-6928<\/li>\n
                                                                                                                                                                                                                              139. Pulley, J. M., Shirey-Rice, J. K., Lavieri, R. R., Jerome, R. N., Zaleski, N. M., Aronoff, D. M., Bastarache, L., Niu, X., Holroyd, K. J., Roden, D. M., Skaar, E. P., Niswender, C. M., Marnett, L. J., Lindsley, C. W., Ekstrom, L. B., Bentley, A. R., Bernard, G. R., Hong, C. C., and Denny, J. C. (2017) Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics. Assay Drug Dev Technol<\/em><\/li>\n
                                                                                                                                                                                                                              140. Reid, P. R., Bridges, T. M., Sheffler, D. J., Cho, H. P., Lewis, L. M., Days, E., Daniels, J. S., Jones, C. K., Niswender, C. M., Weaver, C. D., Conn, P. J., Lindsley, C. W., and Wood, M. R. (2011) Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe. Bioorg Med Chem Lett<\/em> 21<\/strong>, 2697-2701<\/li>\n
                                                                                                                                                                                                                              141. Rodriguez, A. L., Grier, M. D., Jones, C. K., Herman, E. J., Kane, A. S., Smith, R. L., Williams, R., Zhou, Y., Marlo, J. E., Days, E. L., Blatt, T. N., Jadhav, S., Menon, U. N., Vinson, P. N., Rook, J. M., Stauffer, S. R., Niswender, C. M., Lindsley, C. W., Weaver, C. D., and Conn, P. J. (2010) Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol Pharmacol<\/em> 78<\/strong>, 1105-1123<\/li>\n
                                                                                                                                                                                                                              142. Rodriguez, A. L., Tarr, J. C., Zhou, Y., Williams, R., Gregory, K. J., Bridges, T. M., Daniels, J. S., Niswender, C. M., Conn, P. J., Lindsley, C. W., and Stauffer, S. R. (2010) Identification of a glycine sulfonamide based non-MPEP site positive allosteric potentiator (PAM) of mGlu5.<\/li>\n
                                                                                                                                                                                                                              143. Rodriguez, A. L., Zhou, Y., Williams, R., Weaver, C. D., Vinson, P. N., Dawson, E. S., Steckler, T., Lavreysen, H., Mackie, C., Bartolome, J. M., Macdonald, G. J., Daniels, J. S., Niswender, C. M., Jones, C. K., Conn, P. J., Lindsley, C. W., and Stauffer, S. R. (2012) Discovery and SAR of a novel series of non-MPEP site mGlu(5) PAMs based on an aryl glycine sulfonamide scaffold. Bioorg Med Chem Lett<\/em> 22<\/strong>, 7388-7392<\/li>\n
                                                                                                                                                                                                                              144. Rook, J. M., Abe, M., Cho, H. P., Nance, K. D., Luscombe, V. B., Adams, J. J., Dickerson, J. W., Remke, D. H., Garcia-Barrantes, P. M., Engers, D. W., Engers, J. L., Chang, S., Foster, J. J., Blobaum, A. L., Niswender, C. M., Jones, C. K., Conn, P. J., and Lindsley, C. W. (2017) Diverse Effects on M1 Signaling and Adverse Effect Liability within a Series of M1 Ago-PAMs. ACS Chem Neurosci<\/em><\/li>\n
                                                                                                                                                                                                                              145. Rook, J. M., Noetzel, M. J., Pouliot, W. A., Bridges, T. M., Vinson, P. N., Cho, H. P., Zhou, Y., Gogliotti, R. D., Manka, J. T., Gregory, K. J., Stauffer, S. R., Dudek, F. E., Xiang, Z., Niswender, C. M., Daniels, J. S., Jones, C. K., Lindsley, C. W., and Conn, P. J. (2013) Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity. Biol Psychiatry<\/em> 73<\/strong>, 501-509<\/li>\n
                                                                                                                                                                                                                              146. Rook, J. M., Tantawy, M. N., Ansari, M. S., Felts, A. S., Stauffer, S. R., Emmitte, K. A., Kessler, R. M., Niswender, C. M., Daniels, J. S., Jones, C. K., Lindsley, C. W., and Conn, P. J. (2015) Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles. Neuropsychopharmacology<\/em> 40<\/strong>, 755-765<\/li>\n
                                                                                                                                                                                                                              147. Rook, J. M., Xiang, Z., Lv, X., Ghoshal, A., Dickerson, J. W., Bridges, T. M., Johnson, K. A., Foster, D. J., Gregory, K. J., Vinson, P. N., Thompson, A. D., Byun, N., Collier, R. L., Bubser, M., Nedelcovych, M. T., Gould, R. W., Stauffer, S. R., Daniels, J. S., Niswender, C. M., Lavreysen, H., Mackie, C., Conde-Ceide, S., Alcazar, J., Bartolome-Nebreda, J. M., Macdonald, G. J., Talpos, J. C., Steckler, T., Jones, C. K., Lindsley, C. W., and Conn, P. J. (2015) Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents. Neuron<\/em> 86<\/strong>, 1029-1040<\/li>\n
                                                                                                                                                                                                                              148. Rueter, S. M., Burns, C. M., Coode, S. A., Mookherjee, P., and Emeson, R. B. (1995) Glutamate receptor RNA editing in vitro by enzymatic conversion of adenosine to inosine. Science<\/em> 267<\/strong>, 1491-1494<\/li>\n
                                                                                                                                                                                                                              149. Salovich, J. M., Sheffler, D. J., Vinson, P. N., Lamsal, A., Utley, T. J., Blobaum, A. L., Bridges, T. M., Le, U., Jones, C. K., Wood, M. R., Daniels, J. S., Conn, P. J., Engers, J., Niswender, C. M., Lindsley, C. W., and Hopkins, C. R. (2010) Discovery of a novel structural class of M4 positive allosteric modulators: Characterization of ML293, N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicotinamide, with CNS exposure in rats.<\/li>\n
                                                                                                                                                                                                                              150. Salovich, J. M., Vinson, P. N., Sheffler, D. J., Lamsal, A., Utley, T. J., Blobaum, A. L., Bridges, T. M., Le, U., Jones, C. K., Wood, M. R., Daniels, J. S., Conn, P. J., Niswender, C. M., Lindsley, C. W., and Hopkins, C. R. (2012) Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor. Bioorg Med Chem Lett<\/em> 22<\/strong>, 5084-5088<\/li>\n
                                                                                                                                                                                                                              151. Senter, R. K., Ghoshal, A., Walker, A. G., Xiang, Z., Niswender, C. M., and Conn, P. J. (2016) The Role of mGlu Receptors in Hippocampal Plasticity Deficits in Neurological and Psychiatric Disorders: Implications for Allosteric Modulators as Novel Therapeutic Strategies. Curr Neuropharmacol<\/em> 14<\/strong>, 455-473<\/li>\n
                                                                                                                                                                                                                              152. Sheffler, D. J., Nedelovych, M. T., Williams, R., Turner, S. C., Duerk, B. B., Robbins, M. R., Jadhav, S. B., Niswender, C. M., Jones, C. K., Conn, P. J., Daniels, R. N., and Lindsley, C. W. (2014) Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: development of a [3.3.0]-based series and other piperidine bioisosteres. Bioorg Med Chem Lett<\/em> 24<\/strong>, 1062-1066<\/li>\n
                                                                                                                                                                                                                              153. Sheffler, D. J., Sevel, C., Le, U., Lovell, K. M., Tarr, J. C., Carrington, S. J., Cho, H. P., Digby, G. J., Niswender, C. M., Conn, P. J., Hopkins, C. R., Wood, M. R., and Lindsley, C. W. (2013) Further exploration of M(1) allosteric agonists: subtle structural changes abolish M(1) allosteric agonism and result in pan-mAChR orthosteric antagonism. Bioorg Med Chem Lett<\/em> 23<\/strong>, 223-227<\/li>\n
                                                                                                                                                                                                                              154. Sheffler, D. J., Wenthur, C. J., Bruner, J. A., Carrington, S. J., Vinson, P. N., Gogi, K. K., Blobaum, A. L., Morrison, R. D., Vamos, M., Cosford, N. D., Stauffer, S. R., Daniels, J. S., Niswender, C. M., Conn, P. J., and Lindsley, C. W. (2012) Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM. Bioorg Med Chem Lett<\/em> 22<\/strong>, 3921-3925<\/li>\n
                                                                                                                                                                                                                              155. Sheffler, D. J., Wenthur, C. J., Brunner, J. A., Daniels, J. S., Morrison, R. D., Blobaum, A. L., Dawson, E. S., Engers, J. L., Niswender, C. M., Conn, P. J., and Lindsley, C. W. (2010) Development of the First Selective mGlu3 NAM from an mGlu5 PAM Hit.<\/li>\n
                                                                                                                                                                                                                              156. Sheffler, D. J., Williams, R., Bridges, T. M., Xiang, Z., Kane, A. S., Byun, N. E., Jadhav, S., Mock, M. M., Zheng, F., Lewis, L. M., Jones, C. K., Niswender, C. M., Weaver, C. D., Lindsley, C. W., and Conn, P. J. (2009) A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning. Mol Pharmacol<\/em> 76<\/strong>, 356-368<\/li>\n
                                                                                                                                                                                                                              157. Shirey, J. K., Xiang, Z., Orton, D., Brady, A. E., Johnson, K. A., Williams, R., Ayala, J. E., Rodriguez, A. L., Wess, J., Weaver, D., Niswender, C. M., and Conn, P. J. (2008) An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat Chem Biol<\/em> 4<\/strong>, 42-50<\/li>\n
                                                                                                                                                                                                                              158. Smith, E., Chase, P., Niswender, C. M., Utley, T. J., Sheffler, D. J., Noetzel, M. J., Lamsal, A., Wood, M. R., Conn, P. J., Lindsley, C. W., Madoux, F., Acosta, M., Scampavia, L., Spicer, T., and Hodder, P. (2015) Application of Parallel Multiparametric Cell-Based FLIPR Detection Assays for the Identification of Modulators of the Muscarinic Acetylcholine Receptor 4 (M4). J Biomol Screen<\/em> 20<\/strong>, 858-868<\/li>\n
                                                                                                                                                                                                                              159. Stansley, B., Fisher, N. M., Gogliotti, R. G., Lindsley, C. W., P.J., C., and Niswender, C. M. (Submitted) Contextual fear extinction induces a hippocampal metaplasticity mediated by metabotropic glutamate receptor 5.<\/li>\n
                                                                                                                                                                                                                              160. Tarr, J. C., Turlington, M. L., Reid, P. R., Utley, T. J., Sheffler, D. J., Cho, H. P., Klar, R., Pancani, T., Klein, M. T., Bridges, T. M., Morrison, R. D., Blobaum, A. L., Xiang, Z., Daniels, J. S., Niswender, C. M., Conn, P. J., Wood, M. R., and Lindsley, C. W. (2012) Targeting selective activation of M(1) for the treatment of Alzheimer’s disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169. ACS Chem Neurosci<\/em> 3<\/strong>, 884-895<\/li>\n
                                                                                                                                                                                                                              161. Tarr, J. C., Wood, M. R., Noetzel, M. J., Bertron, J. L., Weiner, R. L., Rodriguez, A. L., Lamsal, A., Byers, F. W., Chang, S., Cho, H. P., Jones, C. K., Niswender, C. M., Wood, M. W., Brandon, N. J., Duggan, M. E., Conn, P. J., Bridges, T. M., and Lindsley, C. W. (2017) Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides. Bioorg Med Chem Lett<\/em> 27<\/strong>, 2990-2995<\/li>\n
                                                                                                                                                                                                                              162. Turlington, M., Malosh, C., Jacobs, J., Manka, J. T., Noetzel, M. J., Vinson, P. N., Jadhav, S., Herman, E. J., Lavreysen, H., Mackie, C., Bartolome-Nebreda, J. M., Conde-Ceide, S., Martin-Martin, M. L., Tong, H. M., Lopez, S., MacDonald, G. J., Steckler, T., Daniels, J. S., Weaver, C. D., Niswender, C. M., Jones, C. K., Conn, P. J., Lindsley, C. W., and Stauffer, S. R. (2014) Tetrahydronaphthyridine and dihydronaphthyridinone ethers as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu(5)). J Med Chem<\/em> 57<\/strong>, 5620-5637<\/li>\n
                                                                                                                                                                                                                              163. Turlington, M., Noetzel, M. J., Bridges, T. M., Vinson, P. N., Steckler, T., Lavreysen, H., Mackie, C., Bartolome-Nebreda, J. M., Conde-Ceide, S., Tong, H. M., Macdonald, G. J., Daniels, J. S., Jones, C. K., Niswender, C. M., Conn, P. J., Lindsley, C. W., and Stauffer, S. R. (2014) Discovery and SAR of a novel series of metabotropic glutamate receptor 5 positive allosteric modulators with high ligand efficiency. Bioorg Med Chem Lett<\/em> 24<\/strong>, 3641-3646<\/li>\n
                                                                                                                                                                                                                              164. Turlington, M., Noetzel, M. J., Chun, A., Zhou, Y., Gogliotti, R. D., Nguyen, E. D., Gregory, K. J., Vinson, P. N., Rook, J. M., Gogi, K. K., Xiang, Z., Bridges, T. M., Daniels, J. S., Jones, C., Niswender, C. M., Meiler, J., Conn, P. J., Lindsley, C. W., and Stauffer, S. R. (2013) Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254). J Med Chem<\/em> 56<\/strong>, 7976-7996<\/li>\n
                                                                                                                                                                                                                              165. Utley, T., Haddenham, D., Salovich, J. M., Zamorano, R., Vinson, P. N., Lindsley, C. W., Hopkins, C. R., and Niswender, C. M. (2011) Synthesis and SAR of a novel metabotropic glutamate receptor 4 (mGlu4) antagonist: unexpected ‘molecular switch’ from a closely related mGlu4 positive allosteric modulator. Bioorg Med Chem Lett<\/em> 21<\/strong>, 6955-6959<\/li>\n
                                                                                                                                                                                                                              166. Walker, A. G., Wenthur, C. J., Xiang, Z., Rook, J. M., Emmitte, K. A., Niswender, C. M., Lindsley, C. W., and Conn, P. J. (2015) Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction. Proc Natl Acad Sci U S A<\/em> 112<\/strong>, 1196-1201<\/li>\n
                                                                                                                                                                                                                              167. Weaver, C. D., Sheffler, D. J., Lewis, L. M., Bridges, T. M., Williams, R., Nalywajko, N. T., Kennedy, J. P., Mulder, M. M., Jadhav, S., Aldrich, L. A., Jones, C. K., Marlo, J. E., Niswender, C. M., Mock, M. M., Zheng, F., Conn, P. J., and Lindsley, C. W. (2009) Discovery and development of a potent and highly selective small molecule muscarinic acetylcholine receptor subtype I (mAChR 1 or M1) antagonist in vitro and in vivo probe. Curr Top Med Chem<\/em> 9<\/strong>, 1217-1226<\/li>\n
                                                                                                                                                                                                                              168. Wenthur, C., Daniels, J. S., Morrison, R., Engers, J. L., Niswender, C. M., Conn, P. J., and Lindsley, C. W. (2010) Development of a Second Generation mGlu3 NAM Probe.<\/li>\n
                                                                                                                                                                                                                              169. Williams, R., Johnson, K. A., Gentry, P. R., Niswender, C. M., Weaver, C. D., Conn, P. J., Lindsley, C. W., and Hopkins, C. R. (2009) Synthesis and SAR of a novel positive allosteric modulator (PAM) of the metabotropic glutamate receptor 4 (mGluR4). Bioorg Med Chem Lett<\/em> 19<\/strong>, 4967-4970<\/li>\n
                                                                                                                                                                                                                              170. Williams, R., Manka, J. T., Rodriguez, A. L., Vinson, P. N., Niswender, C. M., Weaver, C. D., Jones, C. K., Conn, P. J., Lindsley, C. W., and Stauffer, S. R. (2011) Synthesis and SAR of centrally active mGlu5 positive allosteric modulators based on an aryl acetylenic bicyclic lactam scaffold. Bioorg Med Chem Lett<\/em> 21<\/strong>, 1350-1353<\/li>\n
                                                                                                                                                                                                                              171. Williams, R., Niswender, C. M., Luo, Q., Le, U., Conn, P. J., and Lindsley, C. W. (2009) Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). Part II: Challenges in hit-to-lead. Bioorg Med Chem Lett<\/em> 19<\/strong>, 962-966<\/li>\n
                                                                                                                                                                                                                              172. Williams, R., Zhou, Y., Niswender, C. M., Luo, Q., Conn, P. J., Lindsley, C. W., and Hopkins, C. R. (2010) Re-exploration of the PHCCC Scaffold: Discovery of Improved Positive Allosteric Modulators of mGluR4. ACS Chem Neurosci<\/em> 1<\/strong>, 411-419<\/li>\n
                                                                                                                                                                                                                              173. Willis, B. S., Niswender, C. M., Su, T., Amieux, P. S., and McKnight, G. S. (2011) Cell-type specific expression of a dominant negative PKA mutation in mice. PLoS One<\/em> 6<\/strong>, e18772<\/li>\n
                                                                                                                                                                                                                              174. Wood, M. R., Noetzel, M. J., Engers, J. L., Bollinger, K. A., Melancon, B. J., Tarr, J. C., Han, C., West, M., Gregro, A. R., Lamsal, A., Chang, S., Ajmera, S., Smith, E., Chase, P., Hodder, P. S., Bubser, M., Jones, C. K., Hopkins, C. R., Emmitte, K. A., Niswender, C. M., Wood, M. W., Duggan, M. E., Conn, P. J., Bridges, T. M., and Lindsley, C. W. (2016) Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core. Bioorg Med Chem Lett<\/em> 26<\/strong>, 3029-3033<\/li>\n
                                                                                                                                                                                                                              175. Wood, M. R., Noetzel, M. J., Melancon, B. J., Poslusney, M. S., Nance, K. D., Hurtado, M. A., Luscombe, V. B., Weiner, R. L., Rodriguez, A. L., Lamsal, A., Chang, S., Bubser, M., Blobaum, A. L., Engers, D. W., Niswender, C. M., Jones, C. K., Brandon, N. J., Wood, M. W., Duggan, M. E., Conn, P. J., Bridges, T. M., and Lindsley, C. W. (2017) Discovery of VU0467485\/AZ13713945: An M4 PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia. ACS Med Chem Lett<\/em> 8<\/strong>, 233-238<\/li>\n
                                                                                                                                                                                                                              176. Wood, M. R., Noetzel, M. J., Poslusney, M. S., Melancon, B. J., Tarr, J. C., Lamsal, A., Chang, S., Luscombe, V. B., Weiner, R. L., Cho, H. P., Bubser, M., Jones, C. K., Niswender, C. M., Wood, M. W., Engers, D. W., Brandon, N. J., Duggan, M. E., Conn, P. J., Bridges, T. M., and Lindsley, C. W. (2017) Challenges in the development of an M4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs. Bioorg Med Chem Lett<\/em> 27<\/strong>, 171-175<\/li>\n
                                                                                                                                                                                                                              177. Wood, M. R., Noetzel, M. J., Tarr, J. C., Rodriguez, A. L., Lamsal, A., Chang, S., Foster, J. J., Smith, E., Chase, P., Hodder, P. S., Engers, D. W., Niswender, C. M., Brandon, N. J., Wood, M. W., Duggan, M. E., Conn, P. J., Bridges, T. M., and Lindsley, C. W. (2016) Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition. Bioorg Med Chem Lett<\/em> 26<\/strong>, 4282-4286<\/li>\n
                                                                                                                                                                                                                              178. Wu, H., Wang, C., Gregory, K. J., Han, G. W., Cho, H. P., Xia, Y., Niswender, C. M., Katritch, V., Meiler, J., Cherezov, V., Conn, P. J., and Stevens, R. C. (2014) Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science<\/em> 344<\/strong>, 58-64<\/li>\n
                                                                                                                                                                                                                              179. Yin, S., and Niswender, C. M. (2014) Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications. Cell Signal<\/em> 26<\/strong>, 2284-2297<\/li>\n
                                                                                                                                                                                                                              180. Yin, S., Noetzel, M. J., Johnson, K. A., Zamorano, R., Jalan-Sakrikar, N., Gregory, K. J., Conn, P. J., and Niswender, C. M. (2014) Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS. J Neurosci<\/em> 34<\/strong>, 79-94<\/li>\n
                                                                                                                                                                                                                              181. Yin, S., Zamorano, R., Conn, P. J., and Niswender, C. M. (2013) Functional selectivity induced by mGlu(4) receptor positive allosteric modulation and concomitant activation of Gq coupled receptors. Neuropharmacology<\/em> 66<\/strong>, 122-132<\/li>\n
                                                                                                                                                                                                                              182. Zhou, Y., Chun, A., Gogliotti, R. D., Dawson, E. S., Vinson, P. N., Niswender, C. M., Noetzel, M. J., Rook, J. M., Bridges, T. M., Daniels, J. S., Jones, C., Conn, P. J., Lindsley, C. W., and Stauffer, S. R. (2010) Pure Positive Allosteric Modulators (PAMs) of mGlu5 with Competitive MPEP-Site Interaction.<\/li>\n
                                                                                                                                                                                                                              183. Zhou, Y., Malosh, C., Conde-Ceide, S., Martinez-Viturro, C. M., Alcazar, J., Lavreysen, H., Mackie, C., Bridges, T. M., Daniels, J. S., Niswender, C. M., Jones, C. K., Macdonald, G. J., Steckler, T., Conn, P. J., Stauffer, S. R., Bartolome-Nebreda, J. M., and Lindsley, C. W. (2015) Further optimization of the mGlu5 PAM clinical candidate VU0409551\/JNJ-46778212: Progress and challenges towards a back-up compound. Bioorg Med Chem Lett<\/em> 25<\/strong>, 3515-3519<\/li>\n<\/ol>\n

                                                                                                                                                                                                                                 <\/p>\n

                                                                                                                                                                                                                                 <\/p>\n","protected":false},"excerpt":{"rendered":"

                                                                                                                                                                                                                                CURRICULUM VITAE Colleen M. Niswender, Ph.D. Department of Pharmacology Vanderbilt University Medical Center 23rd Avenue South at Pierce 1215C MRB IV Nashville, TN 37232-6600 Phone:\u00a0 615-343-4303 Fax:\u00a0 (615) 936-6833 E-mail: colleen.niswender@vanderbilt.edu EDUCATION 1986-1987\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0 Undergraduate, University of Akron, Akron, Ohio 1987-1991\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Undergraduate, University of Toledo, Toledo, Ohio 1991\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 B.S., Pharmacy with Honors in Pharmacology, University…<\/p>\n","protected":false},"author":7273,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"tags":[],"class_list":["post-5","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/my.dev.vanderbilt.edu\/niswenc\/wp-json\/wp\/v2\/pages\/5","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/my.dev.vanderbilt.edu\/niswenc\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/my.dev.vanderbilt.edu\/niswenc\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/my.dev.vanderbilt.edu\/niswenc\/wp-json\/wp\/v2\/users\/7273"}],"replies":[{"embeddable":true,"href":"https:\/\/my.dev.vanderbilt.edu\/niswenc\/wp-json\/wp\/v2\/comments?post=5"}],"version-history":[{"count":4,"href":"https:\/\/my.dev.vanderbilt.edu\/niswenc\/wp-json\/wp\/v2\/pages\/5\/revisions"}],"predecessor-version":[{"id":18,"href":"https:\/\/my.dev.vanderbilt.edu\/niswenc\/wp-json\/wp\/v2\/pages\/5\/revisions\/18"}],"wp:attachment":[{"href":"https:\/\/my.dev.vanderbilt.edu\/niswenc\/wp-json\/wp\/v2\/media?parent=5"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/my.dev.vanderbilt.edu\/niswenc\/wp-json\/wp\/v2\/tags?post=5"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}